Agency of the United States Department of Health and Human Services
POPULARITY
Categories
469 episodes with fda
421 episodes with fda
300 episodes with fda
401 episodes with fda
208 episodes with fda
256 episodes with fda
145 episodes with fda
195 episodes with fda
195 episodes with fda
131 episodes with fda
107 episodes with fda
73 episodes with fda
199 episodes with fda
55 episodes with fda
84 episodes with fda
85 episodes with fda
72 episodes with fda
75 episodes with fda
143 episodes with fda
94 episodes with fda
66 episodes with fda
68 episodes with fda
135 episodes with fda
150 episodes with fda
111 episodes with fda
247 episodes with fda
61 episodes with fda
77 episodes with fda
52 episodes with fda
37 episodes with fda
104 episodes with fda
47 episodes with fda
47 episodes with fda
121 episodes with fda
100 episodes with fda
97 episodes with fda
73 episodes with fda
95 episodes with fda
73 episodes with fda
71 episodes with fda
50 episodes with fda
66 episodes with fda
44 episodes with fda
45 episodes with fda
53 episodes with fda
50 episodes with fda
69 episodes with fda
67 episodes with fda
85 episodes with fda
66 episodes with fda
38 episodes with fda
57 episodes with fda
54 episodes with fda
99 episodes with fda
Rejuvenecimiento celular, longevidad y envejecimiento: la ciencia acaba de dar un paso que podría cambiar la historia de la medicina. Hay descubrimientos científicos que parecen sacados de una película, hasta que empiezan a ocurrir en la vida real Hablamos del primer ensayo clínico aprobado por la FDA para intentar rejuvenecer tejido humano, un avance que está despertando preguntas enormes sobre salud, envejecimiento y el futuro de la humanidad. El Dr. José Hernández Poveda, médico experto en longevidad y fundador de Age Reversal en Mallorca, comparte lo que la ciencia está descubriendo sobre la epigenética, el envejecimiento celular y los avances que podrían redefinir la medicina, la salud y la forma en que vivimos nuestros años. Y si hablamos de vivir más y mejor, también vale la pena preguntarnos cómo queremos vivir hoy. Si quieres aprender a generar más ingresos sin vivir estresado ni sacrificar tu paz mental, te invito a mi masterclass: Cómo generar más ingresos con menos estrés.
Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Bonefrog https://BonefrogCoffee.com/ToddGet the new limited release, The Sisterhood, created to honor the extraordinary women behind the heroes. Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeIf you can't practice tough love, you don't really love. Let's practice tough love and examine why Mike Pence, and establishment Republicans like this who I am calling “Trump 2.0”.Episode Links:Mike Pence loves him some war with Iran BREAKING: Senate Leader John Thune confirms HE'S FORCING A VOTE on the SAVE America Act, he will put Democrats ON THE RECORD opposing the 85-15 issue The Republican Party is protecting Ilhan Omar from accountability. Rep Nancy Mace “I tried to subpoena her immigration records, her brother husband's immigration records, and IT WAS REPUBLICANS that killed my motion” It's a Uniparty. One Big Club.URGENT: Big Pharma wins again; Dr. Vinay Prasad is out as the FDA's chief medical's officer. Not coincidentally, stocks of drug companies are soaring.TRUMP: “You gotta lighten up on this, they might have come into our country illegally but they're good people and they're cheap workers. They're working now on farms, in luncheonettes and hotels. We're just focused on getting the murderers out.” So much for mass deportations.Trump: We'll bring in any Iranian refugees that aid the U.S Military! Trump complained about the Afghan INVADERS and now is doing the same thing. This is how we got invaded with people from the Middle East.HOMELAND: Trump's new pick for Secretary of Homeland recently voted to ALLOW "Refugee" Welfare Programs to continue to be funded at Biden-era levels. Mullin also comforted & HUGGED the cop who shot Ashli Babbitt: "He was distraught. I gave him a hug & said 'you did what you had to do.'" He also claimed Republican Senators were too "emotional" over Jan 6 to confirm Trump's pick Ed Martin for DC Prosecutor.Rep. Brian Mast: “Let's talk about Rep. Mace's resolution. Victims deserve protection. Witnesses deserve confidentiality. I voted to ensure survivors aren't forced to deal with the fallout of the public release of their sensitive information. I voted to send the resolution to the Ethics Committee so that it can be amended to adequately protect those who've done the brave thing and come forward.”Rep Anna Paulina Luna comes out and says it. She says the American People hate Congress for how corrupt they are. After both parties blocked disclosing slush funds using tax dollars to pay off their sexual assault charges, she loses it. “That's why the American people hate us”
In this episode, Etienne Nichols sits down with Staci Miller, a Human Factors and UX Strategist at GenUX, to demystify the role of human factors (HF) in the medical device regulatory pathway. Staci explains that many companies mistakenly treat HF as a "box-checking" exercise late in development, leading to costly submission delays or rejections when the FDA finds the documentation fails to tell a cohesive safety story.The conversation dives deep into the technical distinctions between a Use-Related Risk Analysis (URRA) and a User Failure Mode and Effects Analysis (uFMEA). Staci provides a framework for deciding which approach fits your product, emphasizing that while large conglomerates with post-market data may lean toward uFMEAs, startups and those with novel devices should prioritize the URRA to effectively map out user interactions without the crutch of existing market data.Finally, Staci addresses one of the most persistent myths in the industry: the idea that clinical trial data can replace human factors validation. She clarifies that while the two can overlap in specific, premeditated circumstances (such as complex implants like aortic valves), they serve entirely different masters—one focused on clinical efficacy and the other on the safety of the user interface across diverse environments.Key Timestamps04:12 – The common disconnect: Integrating Human Factors into ISO 14971 risk management.06:45 – URRA vs. uFMEA: How to choose based on your post-market data and predicate device status.10:30 – The "Definition of Done": Tracking the lifecycle of HF documentation from phase zero to market release.13:15 – System errors vs. Use errors: How to identify root causes during summative studies.18:50 – The "Clinical Trial Myth": Why efficacy data is not the same as usability validation.22:10 – Design Inputs vs. Design Outputs: The "Blueprint and the House" analogy for FDA submissions.25:40 – The impact of the "Use Environment": Testing for movement in ambulances and lighting in radiology suites.Quotes"The FDA doesn't put things out there just to have a good time... If they've made human factors a requirement and you're treating it as a 'suggestion,' you're giving yourself enough rope to hang yourself." - Staci Miller"People are obsessed with the product themselves—the design outputs. But the FDA wants to see the design inputs. They want to see the blueprints of how you built that house, not just the wallpaper." - Staci MillerTakeawaysPremeditation is Key: If you intend to use clinical trial data for HF validation, it must be planned in the protocol from the start; you cannot retroactively claim clinical data satisfies usability requirements.Map User Groups Early: Distinguish clearly between primary and secondary users. Bloating user sets without explaining how or why they engage with the device complicates your risk profile.Environment Matters: Documentation must account for the physical "10,000-foot view," including noise, lighting, and motion (e.g., an ambulance), as these are often where critical use errors occur.HF is Risk Management: Human factors should not live in a silo. It must align with the scales of harm (negligible to catastrophic) defined in ISO 14971 and work in tandem with Quality and Regulatory teams.ReferencesISO 14971: The global standard for the application of risk management to medical devices.FDA Human Factors Guidance: The primary document outlining expectations for usability testing and documentation.Etienne Nichols: LinkedIn ProfileMedTech 101: URRA vs. uFMEAThink of a uFMEA (User Failure Mode and Effects Analysis) like a car manufacturer looking at an old model to see why the brakes failed in the past—it relies on known data to fix specific parts.A URRA (Use-Related Risk Analysis) is like teaching someone to drive a brand-new type of vehicle (like a spaceship) for the first time. Since you don't have "crash data" yet, you have to carefully map out every single step the pilot takes and imagine every possible way they could push the wrong button in the heat of the moment.SponsorsGreenlight Guru: This episode is brought to you by Greenlight Guru, the only quality management platform designed specifically for the medical device industry. Whether you need to manage your QMS to stay compliant with ISO 14971 or streamline your clinical data through their EDC solutions, Greenlight Guru helps you move faster with less risk.Feedback Call-to-ActionWe want to hear from you! Do you have questions about your specific regulatory pathway or a topic you'd like us to cover? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, or suggestions to podcast@greenlight.guru.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and trends shaping the industry landscape, offering insight into the dynamic interplay between scientific innovation, regulatory challenges, and strategic growth.Starting with the recent departure of Vinay Prasad from the U.S. Food and Drug Administration, particularly from his role as director of the Center for Biologics Evaluation and Research (CBER). Prasad's tenure, though brief, left an indelible mark characterized by controversy and debate over regulatory decisions. His leadership coincided with significant advancements in biologics and gene editing technologies, like CRISPR, highlighting the complexities in balancing innovation with safety standards. Under Prasad's guidance, the FDA faced challenges in navigating these rapid advancements while maintaining rigorous oversight to ensure that new therapies are both effective and safe for public use. Prasad's resignation signals potential shifts in regulatory philosophy at CBER. The biotech industry is watching closely to see how new leadership will influence ongoing and future evaluations of biologics. The change presents an opportunity to reassess how regulatory bodies can better adapt to scientific advancements while ensuring that patient safety remains paramount. The issues faced during Prasad's tenure underscore the need for transparent decision-making and open communication with stakeholders, which are vital for maintaining trust in regulatory processes.Meanwhile, Pfizer has made a strategic entry into the Chinese obesity market with the approval of a GLP-1 drug developed alongside Sciwind Biosciences. This approval represents not only a significant step for Pfizer but also underscores a broader global focus on obesity management. The efficacy of GLP-1 receptor agonists in weight regulation has opened up new market opportunities, highlighting the growing importance of metabolic health solutions in addressing public health challenges.In other news, Johnson & Johnson's Tecvayli-Darzalex combination therapy has received its third national priority recognition from the FDA for treating multiple myeloma. This recognition reflects promising Phase 3 trial results and underscores the critical role of innovative combination therapies in improving outcomes for complex hematologic malignancies. The success of such therapies illustrates how targeted approaches can significantly enhance treatment efficacy and patient quality of life.Strategic acquisitions continue to reshape industry dynamics. Servier's $2.5 billion acquisition of Day One Biopharmaceuticals aims to strengthen its rare cancer portfolio, including a promising glioma drug, Ojemda. This move highlights Servier's commitment to addressing unmet needs in pediatric oncology and rare diseases, emphasizing a broader industry trend towards focusing on niche therapeutic areas with high potential impact.Regulatory activities are gaining momentum as well, with the FDA set to end a nine-month hiatus in advisory committee meetings by reviewing AstraZeneca's oral selective estrogen receptor degrader Truqa. As AstraZeneca seeks to enhance its oncology pipeline, this review signals ongoing innovation in hormone-based cancer therapies and reflects a renewed emphasis on bringing novel treatments to market efficiently.Additionally, Glenmark Pharmaceuticals has achieved a significant milestone with FDA approval for its generic version of GSK's asthma inhaler Flovent. This development exemplifies efforts to improve access to respiratory treatments by providing cost-effective alternatives to branded medications, potentially reducing healthcare costs while enhancing patient access.On an international scale, Taiwan has announced a substantial investment plan aimed at bolstering its drugSupport the show
From posting products nobody cares about to teaching 800,000 cedis worth of value on TikTok, and why the brutal truth about selling anything online is that no one cares about your camera, your shoes, or your feminine hygiene products unless you show them the problem it solves, how to use it, and why their life needs it right now, the entrepreneur who discovered that the woman selling products for 350 cedis was just posting pictures assuming everyone knew what it does when ladies had no idea because African homes don't teach feminine hygiene and parents don't sit you down to explain these things, the university graduate who went through problems herself and wished someone was there to help her understand how to take care of herself which created the drive to teach ladies what they need to know instead of just selling products, the TikTok strategy that made 800,000 cedis and more because she wasn't there to dance and fool around but to sit down and give explicit knowledge that celebrities, pastors' wives, and mothers never had, the haters who said she didn't make that money and her response of "I don't care, the money is in my account not yours, I made more than that" because when you know your product works and you're giving value you don't care what people say, the Alibaba journey where she taught herself how to order from China by playing on the app, watching YouTube videos, and learning without waiting for someone to sell her a course or sit her down because no one has your time, you should have your own time, the beginner advice to identify the problem your product solves first before you even think about suppliers or shipping because if you're selling anything you need to know what problem it solves and who your audience is, the FDA approval battles that became her biggest challenge when products come with one name but FDA changes it after she's already marketed it creating confusion, the ingredients research she does on every product because "if I didn't want to die I wouldn't want you to die" so she uses her own products and learns about what's inside them, the lab analysis costing 1,000 to 3,000 cedis and FDA registration for imported products at $500 proving you need money to do things right but you can start by reselling other people's products if you have knowledge about what you're selling, the camera example where posting "I'm selling a camera" means nothing but showing phone camera versus real camera quality, explaining why someone serious would choose the camera, demonstrating the value makes people care, the salon analogy that if you open a salon and don't know how to wash hair it will collapse because you just wanted money or had support but didn't have knowledge about salons, the internet wisdom where she doesn't care about gossip, doesn't go online looking for anyone's business, uses her time to learn instead of looking for gossip because anything you want to know is on YouTube, TikTok, free materials that people make available, the verified suppliers on Alibaba for beginners, the AKT shipping company she's used for years because they're reliable, the Turkey and China trips proving she's willing to travel and learn and build an international brand, the people who want to be taught before they take a step when sometimes you need to start, get the idea, play on the apps, watch videos, and figure it out yourself, the realization that when it comes to products you don't need to do your own production from the start but you need to know something about what you're selling because there are people who swallow when they're supposed to insert and insert when they're supposed to swallow, and why the ultimate truth is this: people are usually more focused on the money than the value they give which is where she picked her form because the woman selling for 350 was just posting assuming everyone knew what the product does when people didn't know, but when she came in teaching ladies how to take care of themselves and using the product in addition to that care, when she gave knowledge that African homes don't teach, when she showed up on TikTok not to dance but to educate, when she learned everything from YouTube and the internet without waiting for courses or teachers, when she researched ingredients and used her own products, when she didn't care about haters saying she didn't make 800K because the money was in her account proving her value was real, she wasn't just selling products, she was solving problems and teaching solutions, and that's the only way to build a business that lasts because no one cares about what you're selling until you show them why they need it. Guest: Charity Boateng Host: Derrick Abaitey
Daan Hoek en Thijs Kea ontwikkelden met UV-Smart een revolutionaire technologie die medische apparaten veel sneller reinigt. Ze hebben net een FDA-ticket voor de Amerikaanse markt in handen gekregen.Deze aflevering in het kort:☑️ De weg naar goedkeuring voor de Amerikaanse markt. ☑️ Hoe je een hardware-scale-up financiert en internationaal uitrolt.☑️ Nieuwe tool van Antrophic disrupt hele beroepsgroepenDe zorgsector staat wereldwijd onder enorme druk door personeelstekorten en stijgende kosten. Daan Hoek en Thijs Kea van UV Smart bedachten een nieuwe manier om gebruikte instrumenten te reinigen. Hun D60-systeem desinfecteert medische apparatuur negen keer sneller dan de traditionele methoden en dat zonder het gebruik van chemicaliën. Ze maken hiervoor gebruik van UV-licht. Dit licht dringt door in de cellen van bacteriën, virussen en schimmels en vernietigt hun DNA of RNA. Hierdoor kunnen ze zich niet meer vermenigvuldigen en gaan ze dood.
Les peptides sont partout dans le monde du biohacking et de la longévité.Certains les présentent comme la prochaine révolution en santé.D'autres disent que c'est risqué, mal encadré ou encore expérimental.Alors… qui a raison ?Dans cet épisode, on prend un moment pour sortir du hype et comprendre ce que dit vraiment la science.On parle de :
The ASX 200 cratered another 252 points to 8599 (2.9%), as buyers stepped in as the afternoon wore on. Well off lows, but unconvincing. Oil prices in Asia soared with regional markets falling hard. Across the board losses led by BHP down 5.1% and RIO off 3.8%. Gold miners sold down despite bullion holding up relatively well. NST down 6.2% and EVN off 5.9% with WGX falling 5.7%. Lithium stocks under siege, PLS down 6.7% and MIN off 1.6%. Copper stocks walloped, SFR down 8.2% and other base metal stocks falling. BSL dropped 4.4%. Oil and gas stocks better, but not racing away. WDS up 2.0% and STO up 2.4% with coal stocks better. Uranium stocks dropped, PDN down 7.9% and BOE falling 6.5%. Banks were hit too but off lows, ANZ dropped 2.3% with CBA down 1.8% and the Big Bank Basket falling to $292.41 (-1.9%). MQG fell 2.4% (off lows) with insurers and other financials easier. XYZ fell 4.5% and HUB down 5.4%. REITs fell, GMG off 2.0% and SCG down 3.6%. Industrials were also hit in the Monday flush. BXB down 4.8%, QAN fell 4.5% on higher jet fuel prices, TLS eased 1.3% and healthcare stocks dropped. CSL down 2.8% and RMD off 3.2%. Tech stocks back under pressure again, XRO down 4.8% and TNE off 3.7%. The All-Tech Index fell 3.7%.In corporate news, DNL fell 9.7% on the sale of its fertiliser business. DGT fell 7.4% as its CEO stepped back for a time. PME fell 0.9% despite a renewal of a $40m contract. NAN gained 3.8% on FDA clearance for an expanded range of indications.In economic news, nothing on the local front. 10-year yields jumped to 4.94%. Asian market flushed, Japan down 6.8% (Nikkei), Topix down 4.5%, HK down 2.4% and China down 0.9%. Korea KOSPI down 8.8%.US Futures down. DJ down 831. Nasdaq down 480.Marcus Today – Daily Market InsightsMarcus Today provides clear, practical commentary for self-directed investors – covering markets, portfolios, education, and decision-making without the noise.If you'd like to go further:Start a free 14-day trial of Marcus Today http://bit.ly/mt-trial-podcastJoin Marcus Today Use code MTPODCAST for 10% off http://bit.ly/mt-join-podcast-offerMT20 – Managed ETF Portfolio A professionally managed portfolio run by Marcus Padley and the team, using ASX-listed ETFs with active market timing. http://bit.ly/mt20-podcastPrinciples – How We Think About Investing A short video series on timing, behaviour, and decision-making. No stock tips. http://bit.ly/mt-principles-podcast—Disclaimer This podcast is general information only and does not consider your personal circumstances. It is not personal financial advice.
Check out host Bidemi Ologunde's new show: The Work Ethic Podcast, available on Spotify and Apple Podcasts.Email: bidemiologunde@gmail.comIn this episode, host Bidemi Ologunde explores the rapid rise of prediction and betting markets, and why more people are suddenly treating odds as a serious signal about the future. What is driving their mainstream adoption now? Why are platforms moving beyond sports into politics, economics, and war-risk speculation? And when markets start pricing everything from championship games to the possibility of conflict with Iran, are they revealing collective intelligence, or just turning uncertainty into entertainment?Sponsors and partners:Promeed: 100% mulberry silk pillowcases and bedding that feel incredibly soft, stay breathable, and are naturally gentle on hair and skin.SurviveX: professional-grade FSA/HSA eligible first aid and preparedness kits designed in Virginia, USA and produced in an FDA-registered facility.Alison US CA: Alison is the world's largest free online learning and skills-training platform, helping more than 50 million learners in 193+ countries build career-ready skills with 6,000+ free courses, certificates, and diplomas.eSign (iOS only): eSign is a clean, privacy-first document-signing app that works entirely on your device, letting you sign PDFs, DOCX files, images, and scans, edit and assemble pages, and export crisp 300 DPI PDFs in seconds, without accounts, cloud uploads, or compromising sensitive documents.Support the show
This week’s podcast summarizes some highlights in scientific research and includes a recognition of Rare Disease Week and actions taken by the FDA to ease the criteria for evaluating genetic therapies for rare genetic disorders, the best study to date on the mortality in autism, genetic prediction of outcome in individuals with a diagnosis, and Uta Frith’s commentary on the concept of “spectrum”. https://pubmed.ncbi.nlm.nih.gov/41773580 https://pubmed.ncbi.nlm.nih.gov/41651809 https://pubmed.ncbi.nlm.nih.gov/41661606 https://archive.ph/fPscR
On this episode of Vitality Radio, Jared sits down with Maggie Frank of CV Sciences to unpack the growing federal threat to hemp-derived CBD and low-dose THC products. With potential legislation that could dramatically restrict access as early as November 2026, this conversation explores what's at stake for consumers, retailers, and the natural health community. You'll learn what the proposed changes could mean for over-the-counter CBD products, and why responsible regulation—not prohibition—is the path forward. Jared and Maggie also discuss the importance of consumer education, the role of the endocannabinoid system, and how adults can make informed choices about plant-based wellness options. If you care about supplement freedom, access to hemp products, and protecting natural health choices, this is an episode you won't want to miss.Products:CBD Products - Visit Vitality Nutrition in Bountiful, Utah or call us to order 801-292-6662Additional Information:U.S. Hemp RoundtableVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
In this groundbreaking episode of the Tick Boot Camp Podcast, we interview Dr. Jayakumar Rajadas, a Stanford Medicine researcher who has discovered multiple breakthrough therapeutic candidates for Lyme disease, Babesia, and Bartonella. His work includes the discovery of Disulfiram's effectiveness against Lyme and Babesia, Azlocillin's potent activity against Lyme and Bartonella, and advanced targeted drug-delivery systems designed to preserve the gut microbiome. Dr. Jay's research has been featured in TIME Magazine (Azlocillin) and Forbes (Disulfiram), and connects deeply with the work of leading Lyme researchers, including Dr. Monica Embers (Tulane), Dr. Kim Lewis (Northeastern), Dr. Kenneth Liegner, and Dr. Brian Fallon (Columbia University). This interview delivers hope, science, and unprecedented detail on what may become the next generation of Lyme disease treatments. Key Topics Covered 1. How the Stanford Tick Initiative Sparked a New Era of Drug Discovery In 2012, Stanford launched a major initiative in response to community demand for better Lyme treatments. Dr. Rajadas was selected to lead drug development, focusing specifically on persistent/chronic Lyme disease, where few researchers were working. 2. Understanding Borrelia: Active vs. Stationary Forms & Why Chronic Lyme Persists Dr. J explains the three key survival modes of Borrelia burgdorferi: Active Phase The bacteria are replicating and metabolically active. Easier to kill with standard antibiotics. Stationary Phase Bacteria reach population limits and slow down growth. Represents early persistence mechanisms. Persister Forms Triggered by stressors like antibiotics (e.g., doxycycline). Bacteria fold into round bodies, spiral forms, or compact “cement-like” protective balls. These forms: Shut down metabolic pathways Resist penetration Survive antibiotic exposure Why Doxycycline Can Fail Doxycycline can induce persisters, causing Borrelia to form impenetrable protective shells rather than die. This is why many patients initially feel better, then relapse. 3. Disulfiram (Antabuse): Lyme + Babesia Breakthrough Featured in Forbes One of the biggest scientific shocks of the last decade: Discovery Through Stanford's high-throughput screening of FDA-approved drugs, Disulfiram emerged as a top hit. Clears Borrelia (including persistent forms) Clears Babesia — a major advantage over standard antibiotics Does NOT harm the gut microbiome Is already FDA-approved and widely used for alcohol aversion therapy Highly potent but requires careful dosing due to side effects in inflamed patients. Why Some Patients Improve, and Others Suffer Chronic Lyme patients already have heightened inflammation. Disulfiram is a powerful molecule whose polymorphic forms behave differently in different people. His lab developed: Less toxic formulations Buccal & sublingual delivery systems Rectal delivery options These may reduce neuropsychiatric side effects reported by some patients. Clinical Connections Dr. Kenneth Liegner pioneered clinical use and published cases Dr. Brian Fallon conducted NIH-listed clinical trials. Many clinicians now use Liegner's protocols. Real-world example: Matt shares the story of Brooke Stoddard (Generation Lyme), who regained his life after Disulfiram treatment under Dr. Liegner. 4. Azlocillin: The Antibiotic That TIME Magazine Called a Gamechanger If Disulfiram is the Lyme and Babesia weapon, Azlocillin may be the frontline tool for Lyme and Bartonella. Why Azlocillin Is Revolutionary Eradicates both active and persister forms of Borrelia. Destroys doxycycline-induced “cement ball” persisters by drilling into their vulnerable cell-wall synthesis pathways. Proven effective against Bartonella when paired with azithromycin, based on research by Dr. Monica Embers (Tulane) . The Cell-Wall Vulnerability Breakthrough Persisters STILL must maintain minimal cell-wall synthesis to survive. Azlocillin exploits this tiny vulnerability: It penetrates the protective sphere Breaks the “cement wall” Forces the bacteria out of hibernation Kills them rapidly This discovery is one of the biggest scientific leaps in Lyme research in a decade. The Delivery System That Protects the Gut Microbiome Azlocillin is extremely hydrophilic, making absorption difficult.Dr. Jay fixed this by creating: A magnesium-lipid nanoparticle formulation Designed to release in the upper intestine Avoiding the colon (where most microbiome lives) This allows: High bloodstream absorption Minimal microbiome damage Oral availability of a drug previously only available via IV Why Azlocillin May Be Better Than Disulfiram Hits Borrelia + Bartonella Stronger anti-inflammatory effects No polymorphism issues Fewer side effects Potent against persisters A company is preparing to bring his oral formulation to clinical trials by next year. 5. Loratadine (Claritin): The First Clue from 2012 Before Disulfiram and Azlocillin, Dr. Jay's lab identified Loratadine (Claritin) as a manganese transporter inhibitor of Borrelia. Why it mattered: Borrelia uniquely relies on manganese, not iron. Blocking manganese uptake may weaken the bacteria. The discovery went viral, with many patients reporting improvement even at OTC doses—though the binding affinity was weak. This project introduced the concept of drug repurposing for Lyme to the scientific community. 6. Melittin (Bee Venom) — The Micro-Needle Patch Alternative Bee venom therapy is widely used in the Lyme community, but risks stings and allergic reactions. Dr. J is developing: Melittin micro-needle patches Delivering the active peptide without stinging Using dissolvable, painless needles A safe, controlled, pharmaceutical-grade delivery approach This could modernize bee venom therapy and make it more accessible. 7. Mechanism of Brain Fog & Fatigue in Lyme: A Major Breakthrough Dr. Jay's lab published a neuroscience paper demonstrating: Outer Surface Protein (Osp) Nanoparticles Borrelia sheds lipid-coated outer membrane particles. These form stable nano-vesicles that: Enter the bloodstream Cross into the brain Cause mitochondrial dysfunction Reduce ATP production Result: Brain Fog, Fatigue, Cognitive Dysfunction This explains why neurological Lyme can persist even after bacterial levels drop. This work ties strongly to ongoing research at Columbia University under Dr. Brian Fallon. 8. Collaborations With World Leaders in Lyme Research Dr. J's research intersects with: Dr. Kim Lewis (Northeastern University) Reproduced and validated Disulfiram findings publicly. Helped launch interest in persister-killing therapies. Dr. Monica Embers (Tulane University) Demonstrated Azlocillin + Azithromycin effectiveness against Bartonella. One of the world's foremost experts in persistent infection models. Dr. Kenneth Liegner Early clinical pioneer of Disulfiram therapy. Published stunning recovery cases. Dr. Brian A. Fallon (Columbia University) Leading psychiatrist specializing in post-treatment Lyme. Conducted planned Disulfiram clinical trials. These collaborations form a powerful network accelerating treatment development. 9. New Anti-Inflammatory Discoveries: Galangin & More Dr. Jay recently co-authored a 2025 paper on: Galangin (Thai ginger rhizome extract) Which may reverse cardiac inflammation and fibrosis His team is also exploring other nutraceutical molecules for chronic inflammation relief in Lyme patients. 10. Dr. Jay's Personal Story of Illness and Hope He reveals for the first time: He was diagnosed with Stage 3 Multiple Myeloma Lost the ability to walk Suffered unbearable pain After cutting-edge therapies and research, he is now in full remission His message to Lyme patients: “There is ALWAYS hope.”
U.S. President says Iran will be hit hard on Saturday, as he weighs new targets. One week into the Iran war, the risks for the U.S. and the administration multiply. Tehran apologizes to its Gulf neighbors but strikes escalate. Hundreds of thousands flee Israeli bombs in Beirut. Russian President Vladimir Putin calls for an immediate end to the Iran war. And the FDA vaccines chief will step down in April. Plus, Formula One enters a new era. Listen to the Morning Bid podcast here. Sign up for the Reuters Econ World newsletter here. Listen to the Reuters Econ World podcast here. Find the Recommended Read here. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices
From 500 products sold in three weeks on Snapchat to 90% of sales driven by TikTok, and why the brutal truth about social selling success is that you can't just post products and expect people to buy because nobody cares about your shoes or your MacBook unless you show them why they need it, how to style it, and what problem it solves in their lives, the first 24 hours when one product posted on Snapchat with one paid influencer brought 100+ orders and 20,000 cedis in sales proving that giving value instead of just posting products is what makes people ready to pay immediately, the supplier who was tired after one day because she was just putting products in rubber bags and sending them out when a product of that magnitude requires proper packaging and branding, the moment when customers were getting angry and going back to influencers saying she scammed them because she took their money but products were sold out and she didn't know how to pause orders, the bold move of ordering 10,000 pieces instead of 3,000 when she realized people were ready to wait and pay if she communicated properly, the Instagram search for wholesale suppliers, designers, containers, and stickers because everything needed to be done fast when customers had no patience, the 80,000 cedis invested in influencer marketing to make sure her feminine hygiene products were on the minds and lips of people even when Snapchat kept deleting her accounts due to competition reporting her, the 600 WhatsApp messages in one day from customers looking for her when she moved platforms because she had built trust by teaching not just selling, the transition to TikTok in 2024 that changed everything because she wasn't there to dance and fool around but to sit down and tell ladies what they need to hear about feminine hygiene, the celebrities, pastors' wives, and mothers who patronize her because they had no idea about the things she talks about and wanted to learn, the 12 to 15 FDA approved products now in her catalog with plans to start her own production of feminine washes after traveling to China to find manufacturers who understood her specific ingredients and target customers, the trip to China where she insisted on a sample phase and FDA approval before committing to large scale production because she's not rushing the process, the decision to move from reselling other brands' feminine washes to creating her own Femlux branded products starting with paw biotech, the TikTok strategy that now drives 90 to 95% of sales compared to the Snapchat era when she had to pay influencers consistently, and why the ultimate truth is this: every product has value whether it's clothes, shoes, cameras, or feminine hygiene, but if you're just posting products without teaching people how to style the clothes, which shoes match which dress, why a camera has better quality than a phone, or why feminine hygiene matters and how to take care of yourself, then no one really cares because you're selling not serving, but when you give value first, when you make customers feel like whatever they're going through you've been through it too, when you're explicit and confident about topics Ghanaians are scared to mention, when you invest 80,000 cedis to put your brand on people's minds and lips, when you teach instead of dance on TikTok, when you show phone camera versus real camera quality or tell business owners why they need an iPad, you're not just building a business, you're creating a community that will find you on WhatsApp when Snapchat deletes your account, that will wait and pay when products are sold out, that will grow your sales from 20,000 in 24 hours to a brand expanding into its own production because value is the basis of every business. In this raw episode of Konnected Minds, host Derrick Abaitey sits down with Charity Boateng, the founder of Femlux who dismantles the dangerous "just post your products on social media and wait for sales" mentality that keeps small business owners stuck with zero engagement, revealing the exact moment when posting one feminine hygiene product on Snapchat with one paid influencer brought 100+ orders and 20,000 cedis in 24 hours because she wasn't just selling, she was teaching ladies why they need the product and giving them knowledge they never had, when the supplier got tired after one day and she had to think on her feet ordering 10,000 pieces instead of 3,000 even though customers were angry thinking she scammed them, when competition started reporting her Snapchat accounts and she moved to WhatsApp getting 600 messages in one day from customers looking for her because she had invested 80,000 cedis in influencer marketing to put her brand on people's minds and lips. Guest: Charity Boateng Host: Derrick Abaitey
In episode 2018, Jack and Miles are joined by comedian and host of Abolish Everything, Chandler Dean, to discuss… Noem’s TERRIBLE Week, RFK Jr vs Dunkin, You Can Blame Big Oil and Big Golf For Daylight Saving Time and more! Tillis to Noem: "Those are bad decisions made in the heat of the moment, not unlike what happened in Minneapolis." Rep. Kamlager-Dove enters articles in the congressional record with headlines like, "Lewandowski taking out trash at Noem's DC home" and "ICE Barbie's mile high private chamber with alleged lover exposed" Noem Gets Grilled Over Government Contracts RFK Jr vs Dunkin RFK Jr. took aim at Dunkin'. Mass. residents threatened revolts Your favorite iced summer coffee could contain 46 teaspoons of sugar — the same as drinking 5 cans of Coke British Columbia Will Change Clocks on Sunday for the Last Time 7 Things to Know About Daylight Saving Time The dark side of daylight saving time B.C.'s premier is celebrating the move to permanent daylight time. Others aren't so sure Bill To Make Daylight Saving Time Permanent Stalls In Congress Again What Happened the Last Time the U.S. Tried to Make Daylight Saving Time Permanent? The Real Reason Why Daylight Saving Time Is a Thing The stakeholders of daylight saving time Golf industry tees up fight to keep daylight saving time The business of Daylight Saving Time, from golf to oil 9 Things You Probably Don't Know About Daylight Saving Time The Reasoning Behind Changing Daylight-Saving Is permanent daylight saving time a good idea? Lobbyists, lawmakers and sleep experts are split. What would ‘half-daylight saving time’ look like? LISTEN: Mesa Mesa by YuufSee omnystudio.com/listener for privacy information.
Parmesan cheese scandal exposed: many “100% Parmesan” brands contain up to 20% wood shavings, sawdust, and lint—FDA-approved fillers you're eating on spaghetti and meatballs. Opie Radio podcast with Opie and Ron the Waiter dives into the gross truth behind store-bought Parmesan cheese, fake severed thumb restaurant scams, pubic hair on pizza slices in NYC, Trump's Oval Office religious leaders prayer circle, World War III religious war theories for Armageddon and Jesus return, AI taking jobs and possibly bringing back dinosaurs, Dee Snider health issues ending Twisted Sister tours, plus classic FU Friday rants on soggy paper straws and more. Raw, humorous, no-BS conversations with real talk and storytelling. Subscribe for unfiltered episodes every week—new Opie Radio podcast drops Fridays. Leave a review and tell us what bothers you this week!
This hidden ingredient in junk food is quietly destroying your health. Uncover the harmful food additives and food industry secrets that leave you sick, yet still hungry for more. Learn how these hidden junk food ingredients sabotage your gut health and how you can avoid them starting today.Download Dr. Berg's Free Daily Health Routine: https://drbrg.co/45qtO07This dangerous ingredient in junk food acts as a detergent in your gut. This toxic food additive destroys the protective layer that lines your digestive tract, similar to the way dish soap removes grease from a pan. Once this protective layer is gone, you can develop a leaky gut, allowing toxic food additives, bacteria, and partially digested food into your bloodstream.Harmful food additives are often hiding in ice cream, chocolate, salad dressing, plant-based milk, bread, peanut butter, coffee creamer, mayo, baby formula, and the list goes on! This toxic ingredient is found in 60% of all packaged foods, and goes by names like polysorbate 80, carboxymethylcellulose, and carrageenan. These hidden ingredients in junk food are called emulsifiers. Emulsifiers force oil and water to mix so that the processed food appears smoother or creamy in texture and has a longer shelf life. There is a thick layer of mucus that coats the inside of the intestines, which acts as a built-in protective mechanism for your gut. Emulsifiers dissolve this protective layer over time, allowing bacteria to enter your bloodstream. Your immune system tags them as pathogens, causing an immune reaction and chronic gut inflammation. Gut health directly affects your cognitive function. If you have gut inflammation, you might experience brain fog, sluggishness, and the inability to think clearly after eating. In animal studies, polysorbate 80 caused metabolic syndrome, weight gain, blood sugar problems, and altered gut bacteria. Although no long-term human studies have been published, a human trial published in 2024 found that participants had altered gut microbiomes after just 2 weeks of eating emulsifiers. In the US, food additives can be self-classified as generally recognized as safe (GRAS). Junk food companies do not have to submit long-term human trials to the FDA. The easy solution to this problem is to avoid ultra-processed foods. Instead of focusing on willpower and discipline, avoid buying junk foods altogether. Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.
What happens when one of the most disciplined bodies in the world can't do the one thing everyone assumes it should? On this episode -- one of our most downloaded of all time -- Ali sits down with Mathilde Froustey, principal dancer at the San Francisco Ballet and widely considered one of the most extraordinary dancers in the world.Born in Bordeaux, France, Mathilde began dancing at just nine years old, training at the prestigious Marseille National School of Ballet and the Paris Opera Ballet School before rising to the top of the international ballet world. Onstage, her body is her instrument — powerful, precise, and seemingly unstoppable. But behind the curtain, Mathilde has been fighting battles that almost no one in the dance world talks about. In this candid and emotional conversation, she opens up for the first time about her experience with infertility — a subject she says remains deeply taboo in professional dance. Mathilde shares what it was like to go through IVF while performing at the highest level, navigating intense body scrutiny, and hearing painful comments about her appearance during one of the most vulnerable periods of her life. She also talks about her past struggle with an eating disorder, the pressure dancers face to maintain a certain body type, and the silent toll of trying to build a family inside a culture that rarely makes space for it.“In the dance world, infertility is a taboo subject,” Mathilde says.Not anymore.This is a powerful conversation about perfection, pressure, and what it means to reclaim your body — both onstage and off.EPISODE SPONSORS: THE WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe 3-book bundle is now just $49 (normally $79)!The latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.PHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Go to PherDal.com today and use code INFERTILEAF for $10 off.BELIIG: @belibabywww.belibaby.com Are you thinking about growing your family? Whether you're just starting to plan or are actively trying to conceive, preconception health is key. Beli has vitamins to help both women and men optimize their health before pregnancy. With essential nutrients like Folate, Iodine, and Zinc, Beli ensures your body is ready for this exciting next step. Give yourself and your future baby the best foundation for a healthy start.Visit Belibaby.com today and use code IAF15 for 15% off your first order. Our Sponsors:* Sign up and get 10% off at BetterHelp dot com. Your emotional wellbeing matters. Find support and feel lighter in therapy. Support this podcast at — https://redcircle.com/infertile-af-infertility-and-modern-family-building-through-art/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
uniQure is a business that develops gene therapies. uniQure's AMT-130 is currently in the headlines. This podcast episode attempts to present the Huntington's Disease community's arguments for why the FDA should work collaboratively to design a palatable drug trial. Last week the FDA told uniQure that AMT-130 would be subject to a double blind, Phase 3, randomized controlled study. While the scientific basis for that request is sound in most cases, the Huntington's Disease community argues that path is overly burdensome; perhaps impossible. This episode cites:Dr. Sung - https://www.youtube.com/watch?si=VhMQaFAZRvQA5NRj&t=62&v=mwEEJ91LeJY&feature=youtu.beSr. Sarah Tabrizi - https://www.youtube.com/watch?v=wKj1JRfJBRE&t=356sDr. Ed Wild - https://www.spreaker.com/episode/uniqure-update-with-dr-ed-wild--67900959FDA papers - External Control Guidance https://www.fda.gov/media/122425/downloadUse of Bayesian Statistics - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-productsSenate Committee on Aging - https://www.youtube.com/watch?v=yLm1SltbRxw&t=2702sSponsorship InformationThank you to Trata for sponsoring the show.If you're listening to this podcast, you'll like Trata. Trata is buyside to buyside conversations on individual stocks. Trata makes finding a bull or bear on any stock as easy as clicking two buttons. Over 125 funds globally contribute that collectively cover 2000+ tickers. Trata raised over $3mm coming out of Y Combinator. Before you would track 13Fs, now you can understand what funds are actually thinking. You can join as a lurker or you can join as a contributor and Trata will pay you hundreds of dollars per call. For a free trial, go to trytrata.com/brew OG Sponsor Shoutout!Thank you to Fiscal.ai for sponsoring the show. DISCOUNT INFO: If you use the affiliate link fiscal.ai/brew, you will automatically get 2 weeks of Fiscal Pro for Free and if you find that you want to upgrade, my link will get you 15% off any paid plans. About Fiscal.aiFiscal.ai is the complete modern data terminal for global equities.The Fiscal.ai platform combines a powerful user experience with all the financial data capabilities that professional investors need. Users get up to 20 years of historical financials for all stocks globally that they can easily chart, compare, or export into their own models. And unlike legacy data terminals where it can take hours or even days, Fiscal.ai's data is updated within minutes of earnings reports. Fiscal.ai also tracks all the company-specific Segment & KPI data so you don't have to. Like to track Amazon's Cloud Revenue? They've got it.How about Spotify's premium subscribers? Or Google's quarterly paid clicks?They've got all of it.
Dr. Marc Pietropaoli is an orthopedic surgeon and founder of Victory In Motion, home of Knee Repair, NOT Knee Replacement®. A former fellow of Dr. James Andrews, he has spent more than 25 years advancing regenerative and non-operative orthopedic care. He was the first surgeon in the world to perform an FDA-indicated BEAR ACL repair outside of clinical trials. His mission is bold: make the world Knee Replacement Free by 2043. In this episode, Dr. Mark Pietropaoli shares how he went from traditional orthopedic surgery to pioneering regenerative approaches like stem cells, PRP, laser therapy, and his Victory Method to help people repair knees instead of getting knee replacements. RESOURCES: Learn more about Dr. Pietropaoli here: http://www.victoryinmotion.com Instagram: @drmarcpietropaoli Get his book "Repair Not Replace" here: https://amzn.to/4uclnk3 Get 10% off Peluva minimalist shoe with coupon code COACHTARA here: http://peluva.com/coachtara CHAPTERS: 00:00 – Intro 01:52 – Sponsor: Peluva minimalist shoe ad 03:47 – Dr. Pietropaoli's background 04:35 – Witnessing a knee replacement and asking "Isn't there a better way?" 09:12 – Training, indoctrination, and early exposure to regenerative tools (laser, PRP, PT, nutrition) 21:24 – Stem cells, aging joints, and why knees break down over time 48:51 – The Victory Method, clarity day, and full-body assessment process 53:19 – Testing, imaging, goal‑setting in one visit 53:57 – Virtual care, state licenses, and working with out‑of‑town patients 58:30 – Where to find Dr. Pietropaoli WORK WITH TARA: Are You Looking for Help on Your Wellness Journey? Here's how Tara can help you: TRY TARA'S APP FOR FREE: http://taragarrison.com/app INDIVIDUAL ONLINE COACHING: https://www.taragarrison.com/work-with-me CHECK OUT HIGHER RETREATS: https://www.taragarrison.com/retreats SOCIAL MEDIA: Instagram @coachtaragarrison TikTok @coachtaragarrison Facebook @coachtaragarrison Pinterest @coachtaragarrison INSIDE OUT HEALTH PODCAST SPECIAL OFFERS: ☑️ Upgraded Formulas Hair Test Kit Special Offer: https://bit.ly/3YdMn4Z ☑️ Upgraded Formulas - Get 15% OFF Everything with Coupon Code INSIDEOUT15: https://upgradedformulas.com/INSIDEOUT15 ☑️ Rep Provisions: Vote for the future of food with your dollar! And enjoy a 15% discount while you're at it with Coupon Code COACHTARA: https://bit.ly/3dD4ZSv If you loved this episode, please leave a review! Here's how to do it on Apple Podcasts: Go to Inside Out Health Podcast page: https://podcasts.apple.com/us/podcast/inside-out-health-with-coach-tara-garrison/id1468368093 Scroll down to the 'Ratings & Reviews' section. Tap 'Write a Review' (you may be prompted to log in with your Apple ID). Thank you!
Broadcast from KSQD, Santa Cruz on 3-05-2026: Dr. Dawn demonstrates how to critically read a science paper using a widely-publicized study claiming adolescent cannabis use causes psychotic, bipolar, and anxiety disorders. She identifies multiple methodological problems: only 5.7% of Kaiser adolescents admitted cannabis use versus 11.2% in anonymous national surveys, suggesting massive underreporting; the study conflates any use with heavy use; and with 463,000 participants, trivially small differences become statistically significant but clinically meaningless. She proposes reverse causation—that prodromal schizophrenia symptoms may drive teens to self-medicate with cannabis rather than cannabis causing psychosis. The study also included "disruptive behavior disorder" diagnoses that lack rigorous criteria, and she notes diagnostic codes are sometimes chosen for insurance reimbursement rather than accuracy. While acknowledging high-dose THC before age 16 may affect brain development, she concludes the headlines claiming causation are not supported by the actual findings. Dr. Dawn discusses how aquaculture—now producing 60% of fish consumed globally—has become a breeding ground for antibiotic-resistant pathogens. More antibiotics per kilogram are used in fish farming than in any other animal agriculture, with drugs dissolving into water and sediment where bacteria develop resistance. One study found antibiotic-resistant bacteria in over 80% of shrimp species tested across multiple countries. Through horizontal gene transfer, these resistance genes spread to human pathogens—a 1991 Latin American cholera outbreak affecting nearly a million people may have acquired drug resistance from Ecuadorian shrimp farms. Dr. Dawn reports that the FDA rejected Moderna's mRNA flu vaccine application without even reviewing it, despite trials of 41,000 people showing it was 27% more effective at preventing illness and 29% more effective at preventing hospitalization than existing vaccines. She attributes this to politicized anti-mRNA bias lacking scientific basis, noting that venture capital investors like Blackstone (who invested $750 million) will now avoid vaccine development, effectively handing this critical technology to other countries. Dr. Dawn describes the "wellness industrial complex"—pharmaceuticals, tech, testing companies, and health influencers creating content that pathologizes normal behaviors. YouTube health videos have amassed 200 billion views, and 30% of British respondents now get medical advice from AI chatbots. She cites a 400% increase in British adults seeking ADHD diagnoses, noting that analysis of top TikTok ADHD videos found less than 50% accurately reflected actual symptoms. Many influencers receive undisclosed payments to mention products, and the U.S. and New Zealand are the only countries allowing direct-to-consumer drug advertising. A caller asks about navigating Medicare after their Advantage plan was terminated with no local providers accepting remaining plans. Dr. Dawn explains that Medicare Advantage companies took extra government payments meant for wellness programs but didn't build them, and are now exiting markets as costs rise. She recommends contacting Gray Bears or AARP for free Medicare navigation assistance and suggests exploring regular Medicare with a secondary plan or direct-pay practices. /li>
If you have chronic hives and antihistamines aren't helping, there's a new treatment option to know about. In this episode of The Itch Review, we spotlight "Remibrutinib in Chronic Spontaneous Urticaria" published in The New England Journal of Medicine, March 2025. This article looks at the REMIX trials, which tested whether remibrutinib, a BTK inhibitor, can help adults whose chronic spontaneous urticaria (CSU) is not controlled by antihistamines alone. Remibrutinib works differently from antihistamines. Instead of blocking histamine after it's released, it stops mast cells from releasing those itch-causing chemicals in the first place. The FDA approved remibrutinib in September 2025. What we cover in our episode about the REMIX trial: Understanding CSU: Chronic spontaneous urticaria causes itchy hives and swelling for more than 6 weeks with no clear trigger, and antihistamines don't work for everyone. How remibrutinib works: This BTK inhibitor stops mast cells from releasing chemicals like histamine, rather than blocking histamine after it's already released. Why do two identical trials: Running the same study twice (REMIX-1 and REMIX-2) with different patients helps prove the results are real, not a fluke. Key results: About half of patients reached well-controlled disease, and about 1 in 3 became completely clear of hives and itch. Safety and side effects: Petechiae (tiny dots of bleeding under the skin) were the main thing to watch for, but most cases were mild and went away on their own. DOWNLOAD THE INFOGRAPHIC More resources about chronic hives Chronic Spontaneous Urticaria - Allergy & Asthma Network Chronic Urticaria Toolkit What are hives? All episodes on urticaria *********** The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.
In today's episode, we welcomed Saad Z. Usmani, MD, MBA, FACP, FASCO, to discuss the significance of the January 2026 FDA approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).Usmani is chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York, and the recipient of the 2025 Giants of Cancer Care award for multiple myeloma.In the exclusive interview, Dr Usmani explained the clinical implications of the regulatory decision that expanded the indication for daratumumab plus VRd to the transplant-ineligible setting, detailed the pivotal data from the phase 3 CEPHEUS trial (NCT03652064) that supported the approval, and provided context for treatment strategies with this regimen in clinical practice.
Logan McKnight is the founder of GoodKnight Consulting and a strategic advisor to MedTech executives navigating growth, leadership challenges, and operational complexity. Logan shares her nearly 20-year journey from pre-med to neuromonitoring technologist to CEO, and explains why she now focuses on helping leaders build teams that scale without sacrificing culture or burning out. She discusses lessons learned managing remote surgical service teams, why “simple scales,” and how mission, vision, and values enable better decisions and hiring beyond gut instinct. Guest links: https://www.goodknightconsulting.net/ Charity supported: ASPCA Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com. PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical EPISODE TRANSCRIPT Episode 075 - Logan McKnight [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I am delighted to welcome Logan McKnight. Logan is the founder of GoodKnight Consulting and a strategic advisor to MedTech executives navigating growth, leadership challenges and operational complexity. With nearly 20 years in neuromonitoring and surgical services, including experience as a CEO, VP of Operations and business development leader, Logan brings an experienced perspective to executive leadership. She works with directors, VPs, and C-suite leaders to build teams that can scale without sacrificing culture or burning out. Well, welcome to the show, Logan. I'm so glad to speak with you today, and thank you so much for being here. [00:01:34] Logan McKnight: Yeah, it's great to be here. I appreciate you inviting me. [00:01:36] Lindsey Dinneen: Of course. I'd love if you wouldn't mind starting off by sharing just a little bit about yourself, your background, and what led you to MedTech. [00:01:45] Logan McKnight: Of course. Yeah. So my name is Logan McKnight and I have been in medtech for almost the last 20 years. And I think my journey, I, a lot of people have a very similar like origin story of haphazardly finding their way into medtech. I was pre-med in college. I wanted to go into veterinary school and I think I panicked honestly last minute, not really wanting to go. I interned under vet who basically dissuaded me from doing all the work of vet school and said go to med school. And feeling a little lost, I found my way to medtech, particularly neural monitoring, which was a field, pretty niche, but basically I got trained by a company to go in and run equipment and monitor patient's nervous systems during surgery. And to me, just having my bachelor's degree and having that level of impact and being able to jump right into patient care without having to go to more, you know, years and years of schooling was right up my alley and it's been such a wild ride. You know, I was a technologist and then I became a manager and then VP of development of business development, and head of contracting. And then I went over to a small company where I was the vice president of the whole company, and then eventually CEO, and now I'm consulting for medtech companies. So it's been a really fun journey that I didn't plan at all. [00:03:06] Lindsey Dinneen: Yeah. Okay. Well, excellent. And that brings up so many questions, but to start, so you were thinking originally you might wanna be a vet. Do you have you know, like, did you grow up with animals? Did you just have an amazing love for them? Where did that come from? [00:03:23] Logan McKnight: You know, honestly, I think I would've had way more animals, but my parents were a lot more reasonable than I was. So we just had the regular pets, but I grew up like horseback riding and in the Midwest, in Ohio. So I was around a lot of farm animals and things like that and I was part of like FFA and horticulture. So future Farmers of America. And I actually was really interested in large animals because I didn't wanna deal with people, I didn't wanna deal with people or their pets. So, and you know, and so that was what panicked me about med school was like the whole plan was veterinary school was to avoid the people part. And then I found through medtech you know, neuromonitoring and surgery where my patients are asleep. And so I still got to do all the things that I love, like providing impact, but then, you know, not having to worry about, I guess all for me I just had my head like all the challenges and complications that deal dealing with patients that I thought would make my job and life really difficult. So it's been really fun to kind of focus on just like the care and how to move things forward and explore this big, wide open space of how to impact people's lives in surgery. [00:04:31] Lindsey Dinneen: Yeah. And you know what's interesting about that too is, though, I think it sounds like throughout your, though, as you've, you know, gone from technologist and then you've had all of these amazing career changes and growth basically. It sounds like, you know, you have developed though your own kind of leadership style, so even though maybe originally you weren't sure about dealing with people, so to speak, you've actually excelled at it. So I'm curious how that has evolved for you in creating and managing teams. [00:05:03] Logan McKnight: Yeah. You know, it's interesting. I think like initially I was trying to control all these variables before I got into leadership in people, and then realized like you can't do that once you get to actually working with people. And once you almost like acknowledge and recognize, you can't control that but there's some beauty in that of you just allow for what you allow and then you know, you have to give people the ability to function like at their level. And you create the parameters. But other than that, like some magic happens when you don't try to control every single thing. And I see so many, especially new managers, you know, being like, "I need to control everything." And they're wondering why they're exhausted or their team's not respecting them. And it's like, gotta let go, gotta let go of the wheel a little bit. So, you know, I think those are some lessons and sometimes they just come with time and experience. [00:05:55] Lindsey Dinneen: Yeah, absolutely. Yeah. So, when you started, well, let's go back to the beg, maybe it's kind of at the beginning of your career. What are some things that you learned as a technologist and as you were growing within the hospital systems themselves, that contributed to basically where you would become now to become an entrepreneur and all of that. [00:06:21] Logan McKnight: Yeah, I mean, I will be very honest, and this is not meant to be a dig at anybody who I'd worked with or any boss. But I just, I went to work for a private company and we went and we were almost like hired mercenaries. So we would go to like, you know, every day I was in a different hospital. I didn't know my schedule till the night before. I rarely saw my manager and, you know, rarely saw other members of my team and it really felt like I was very isolated and alone. And it added to my burnout and also feeling like I didn't have anyone watch, like looking out for me and my back as a younger employee. And I realized there was so much room for improvement there in how you manage a team remotely. And so I think I, I just like mentally I was a psychology major before I switched to pre-med, and so I think like the, like human brain, because I was, you know, neuroscience, but like psychology, I think is so fascinating to me and the way people tick and what makes them tick. And I, I'm a big believer if you can figure out the way people tick, you can unlock so many things in the world and like you can, you know, you can be the most brilliant person, but if you can't communicate effectively, if you can't manage a team, you're really not gonna take things to the next level because you're not gonna activate those people around you to perform and get something done. So I feel like it was a case study for me to kind of watch like these managers and struggle and I'm like, "Ah, that's what I'm not going to do." [00:07:47] Lindsey Dinneen: Yes. Yeah. Sometimes learning from examples that maybe you wish you didn't have to learn from though can be the best teachers and actually serve your, you know, your own leadership style and your people that you end up getting to influence. It actually does help in the long term, but so. [00:08:06] Logan McKnight: Totally. [00:08:07] Lindsey Dinneen: So when you started GoodKnight Consulting, what was the impetus for that? I mean, you'd had this you've had this amazing career so far. You're ready kind of just for the next step or what sparked that? [00:08:19] Logan McKnight: You know, it's interesting, I stepped down from my CEO position 'cause I was feeling, I was running a neuromonitoring service company in the Pacific Northwest. We also had a professional services arm with neurologists. And then I had a medical billing company that I was running and we did mostly out of network billing. And then we also started a company in India right before COVID. So by 2023, I was fried, I was very burnt out in the way that I felt like I was busy all the time, but not really having the same impact I used to have. I think a lot of that was like I, I got more involved on the litigious side of running a company and then also the medical billing side really takes it out of you. So the thing I enjoyed was the coaching and the mentoring, and once I took a little bit of a step back and thought about what would I do every day for free? You know, like, what would I just love to do? And the reality was coaching other leaders, especially one like scratched my itch for helping people and provide and like, impact, which I realize is my biggest driver is like, how do I impact the most people and walk away with, you know, my life feeling like I've touched people in a positive way, and I think that's, you know, my, my driving force. So that's kind of why I started. And I started honestly just trying to go to leaders individually and offer some webinars and some one-on-one coaching. And then I really realized working with companies actually is the best way to go about this because you get ownership and leadership that's totally aligned and they want that support for their leaders. And then, it's so much easier to see the impact spread throughout an organization, so that's been really cool, is to be this outside force driving an owner or an executive's vision of what they want their company or the team to be. [00:10:07] Lindsey Dinneen: Yeah, and I noticed when I was reading a little bit more about the company, one of the things that I thought was really interesting is you talk about there, this is not just let's say leadership or mindset coaching or something like that, although that is very important as well. It is also about the business strategy. And you talk a lot about, you know, you've been in the position to understand how much, of course, revenue matters. You ha you have to, you know, make sure that's a strong, you know, foundation for the business. So, so how do you balance the two when you work with clients? [00:10:45] Logan McKnight: Yeah, no, that's a great question. I think every client is unique. I have found that just stripping away-- actually with something I, a blog post I was working on today and something I posted on LinkedIn, and it's something I find myself saying to founders and owner operators all the time-- simple scales. And I think, you know, what ends up happening is a lot of times you get this great idea for a product, a service, a company, and you just go. And you don't sometimes sit down and create like the true mission or the vision and like the values of the company. And it's really hard for owner operators and people who are in startup land and you know, small businesses to pause and do that, especially if they've been going for a few years 'cause you know, it's like, "Well, I've been operating without this stuff. It's totally fine." The reality is it's so much easier to grow and scale and also to gut check yourself when you're making decisions and being like "This is the right call because this aligns with our mission and our vision for the company or our growth initiatives for this year. And then it aligns with my values. I feel good about this decision and I can communicate it to people I hire. So I trust those people." And like that's what scales is, the trust and people having like the unified mission and vision and values and like, I know it sounds a little touchy feely, but the reality is like that's actually what I feel like I end up centering owners and operators on. It's less about the minutia and the details and more about like, does this make sense with where you wanna go and the way you, and the way you wanna get there. [00:12:21] Lindsey Dinneen: Yeah. Yeah, exactly. Okay. Yeah, I really like that. And with the emphasis on the unified team in terms of, you know, we don't all have to view life exactly the same, but we need to be aligned, at least with our mission and values and things like that. What do you find are some of the best practices when it comes to building out a team? And on the flip side, what are some things that maybe are common or that feel like they would be good practices, but in reality might not be. Like, what are some lessons learned, I suppose, on both sides? [00:12:56] Logan McKnight: Yeah. I mean, I think, I'll be honest, I think a lot of owners and maybe leaders who've been in their position for a while, like, like there-- I was talking to somebody else about this, about your gut feeling and like, go with your gut and trust me. I was a big go with my gut leader especially as a CEO, but like that doesn't scale because you have to be able to verbalize like, what are the things you're looking for? Why did you pick this person? And so at the end of the day you know, I had a policy when I was probably right, became, when I became a CEO that I needed to like approve after a couple not so great hires, I needed to approve every hire. And like the reality is that's not realistic, that's not gonna scale as you grow. And so I just needed to create the, this is what we're looking for like, you know, we're hiring for attitude. We can train the aptitude, we can train the technical depending on what the job is. But, you know, here's what we're really looking for, is a good fit for the company and the culture. And then, because once I had people who I knew really got that and saw the vision, I knew they were gonna make the right choices. And so I didn't feel like I had to. Be the one making that decision, I could scale it and help, you know, allow my team to hire for the people in the places that they needed and saw. [00:14:09] Lindsey Dinneen: Yeah. Okay. Yeah, I really like that. So, one thing that I thought was interesting, especially so on your LinkedIn profiles, I was, you know, enjoying reading more about you and some of the things you've done. But you had mentioned that sometimes there's a trade off between hitting targets and then you're burning out your team for the opposite. You're protecting your team, but then you're not hitting your targets. Could you speak a little bit more about that and how you help companies sort of overcome that challenge. [00:14:40] Logan McKnight: No, and I mean, I think it's like, I equate like, I think when I first became a leader, you know, talking about how my viewed my other leaders maybe know what not to do, I definitely swung the pendulum too far the other direction when I first started. And I was way too, I don't know, I was way too, all the things I didn't get. And so two, like checking in with my team, "How are you doing?" Not wanting to delegate work to them and doing these things because you know, and so I realized there's you, I think that's like an initial thing a lot of leaders go through is that shift. It's when you get stuck in the one extreme or the other and you don't really find your good at equilibrium, that it's really hard to sustain. And I think it's really important to find your equilibrium of, like, "This drives us to hit quota. This drives us to get our metrics and to for success. And then it does it in a sustainable way that our team's gonna stay." Because to me, like, sustainable. I kind of was thinking about my values even this morning and I'm like, I think fun is really one of my values like, I want to really enjoy like not just my personal life, but my professional life, and I think your job, your company, all of those things is a lot more fun when it's sustainable, right, when you're like exhausted. So finding a way for it to be sustainable for your team, for, you know, and everyone likes to win. Like it's fun to hit quota. It's fun to like crush your metrics and celebrate. So it, how do you know, make that sustainable and fun? And I think that's like a long-term success or recipe for success with a company. [00:16:15] Lindsey Dinneen: Yeah. Yeah. Well, and you know, it's so interesting 'cause actually this has come up a couple of times recently on the podcast is the sort of core value of fun and how much that does actually transform people's experience with the company. And you know, because inevitably you're gonna have those days that are just really tough and hard. And so being able to though have a culture of fun and joy is, it does make a difference. Yeah. [00:16:42] Logan McKnight: No, for sure. I remember when I first started working in surgery and someone asked me, they're like, "Oh, is it like Grey's Anatomy?" And, you know, and I'm like, "It's not nearly as like sexy. Like there's no, you know, doctors in closets and whatever." The, I, it's actually more like the show Scrubs and the reality is, and people are like, "Oh, that seems like goofy and comedy." I'm like, "I know." But the, I think the reality is we view in like healthcare and medtech of like this, you know, taking care of patients, a serious job. We're talking to surgeons. But for anybody who's really good at their job, like, you know, you see, especially in surgery in these high stakes environments, like it's actually the best rooms to be in are a lot of fun because you rely on your team, you know everyone's gonna do well, or you know their job well. If shit hits the fan, the tone changes and you can trust that. But I think because you trust your team. It's fun, you know, in more moments than not because there's just so much trust that when things get serious, people will speak up and it's safe. I think you like when you're psychologically safe, it's enjoyable, it's fun, and you also feel like you can speak up when you say something wrong. And I feel like those are the healthiest like work dynamics, both in healthcare then, especially in medtech when you're putting a product out there, like you want somebody to say something if they see a problem with your product before it goes to market, right? [00:18:05] Lindsey Dinneen: Well, and I love that. I love that perspective too of, you're absolutely right, healthcare, medical devices, it is it is serious by nature and it should be like, we should take our jobs seriously. But at the same times, if we could not maybe take ourselves as seriously and, you know, and infuse the fun and it does help also I think dissipate some of that-- well, some of the really hard, you know, again, those days that are tough it helps to be able to say, you know, take a step back and go, you know what, "It's yes, and." [00:18:37] Logan McKnight: Right. A hundred percent. Yeah. It adds a little like, like brevity to those se really serious moments to be able to feel. You know, and I think that at the end of the day, like you being in whatever place whatever your place is in healthcare, in medtech, like whatever role you're playing, like you are helping advance the field, you're helping patient care. And I think always keeping that in mind, even on like the tough days, like you're advancing something in a good way keeps you centered on like your why and drives you forward in a really good way versus like, you know, and I'll be honest, like I, it got hard for me in my CEO role, like, I think I lost my why a little bit and my driver, because it's very hard to see, "Okay, well how am I impacting patient care positively. How am I impacting the world positively?" when you're chasing down insurance reimbursements and whatnot. And, you know, dealing with hospital shutdowns during COVID. So I think at the end of the day, I realize like I need to find a way for this to be enjoyable and fun because I also realize like I'm my best self and I'm more creative and I'm more in like a problem solving zone when I'm in that, that good mindset. And so I, I look at it as a huge positive to, to figure out what, what drives you and make you happy. [00:19:51] Lindsey Dinneen: Yeah. What drives you makes you happy. And I agree with you, if you can also take a step back sometimes and have that broader perspective and mix it with just a little bit of humor, even if just all you're doing is taking a quick break and watching, I don't know, a funny cat video or something. Yeah. [00:20:10] Logan McKnight: Sure. [00:20:11] Lindsey Dinneen: Reset moments make a difference. So difference, you're a board member of several organizations and I wondered if you could speak a little bit to those organizations and what led you to get involved with them. [00:20:24] Logan McKnight: Yeah. So the two I'm on the board of is one Nepal's Spine Foundation which I went to Nepal with a few surgeons I worked with. And then when I was in figuring out my why when I stepped away the surgeons who are started the foundation invited me to join the board. And actually I will be going to Nepal with them in April and we'll be doing another mission and then hiking to Everspace camp together. I'm looking forward to that, and it's been amazing 'cause I think that's also, I've gotten to go on a lot of mission trips in my career. I've gotten to go to Ghana and Barbados, Dominican Republic, Nepal, India. And so, like I also realized like impact being my driver, like I have so much impact to teach people about neuromonitoring, which isn't a well-known, you know, aspect of surgery always. And so the fact that I could leave a hospital, a community better for going there really was a driver. So the fact that I continued to do that work is really important. And then the second is STRIPES, which is how I met you, women in medtech. And you know, the nice thing is I was looking, I was a, I went back before I fully launched GoodKnight Consulting and became like a device rep just to kind of figure out, you know, do I wanna go back into sales? What do I really wanna do? And I was a little lost and I found my way, you know, I wanted community. And when I found this group, it was just transformative for me. Like I, my mentor was Lisa Jacobs, who is phenomenal and has been inspiring for a very long time. And she actually really pushed me to do my dream and start and really put all into my coaching and consulting. So I'm really grateful for that. And then she invited me to be on the board. So like to continue to give back to an organization that I feel like personally gave me, like it, it's why I am where I am today. It gave me that push I needed in that support. And there's tons of women in the organization like Claire Davis, Kat Hurd, like Courtney Turich. I just, they're all out there, they're all public on LinkedIn. And that was something that honestly, initially scared me. And so just, I was inspired by them, supported, and I think that's a really, you know, great thing when you are becoming an entrepreneur is finding your community and that support. [00:22:42] Lindsey Dinneen: Yeah. Yeah. Well, okay. So I just, I love the fact that you're doing both of those things. The mission work is really cool. It's amazing to hear how you've gotten to use-- well, because you're so driven by impact how you've gotten to do that and then make a big difference in, in the lives of people that, yeah, may otherwise never have had that opportunity or, you know, at least not for a while or whatever. So. [00:23:09] Logan McKnight: Right. [00:23:10] Lindsey Dinneen: Yeah, that, that's really incredible. So, you know, through that or throughout your career, are there any moments that really stand out to you as kind of affirming, "Wow, I am in the right industry at the right time." [00:23:23] Logan McKnight: You know, I think medtech, like always, even if it's not me and something I'm doing, like seeing people who I know in the industry and accomplishments they've made, and organizations that I've either been a part of or supported in some way in my career, like just seeing like the new tech coming out and the advancements they're making, just reaffirms like I'm part of a bigger picture in an ecosystem that's really great. And even, you know, like I, I came from the spine space when I was doing medical device and it spine is, you know, tough. Like ortho's tough, spines tough. That's a lot of competition. But you know, I think. Competition drives quality, and so it's really cool even if you see your competitor doing something, you know, you're like, "Oh man, I wish we would've," but it's getting done. It's, you know, it's pushing the envelope, it's making it better. And I think that's huge. And, you know, really exciting too when I found you and Project Medtech to see how you guys are helping support like startups and investors and people who are looking to get into this space. Because I think that's the other thing is getting fresh perspective and new innovative companies helps everybody like drive, drives the mission forward, drives the impact forward on patient care. [00:24:38] Lindsey Dinneen: Yeah. Yeah. I love that. Yeah. And okay, so another very random thing that I found on your LinkedIn, but I just really liked it 'cause I resonate with this aspect. So you started to paint, you learned how to paint. Tell us about that and does that play a role in your creativity overall, do you think? [00:25:01] Logan McKnight: You know, I think so. So I hosted like a happy hour for girlfriends and we did this thing where we painted like a thrift shop thrift store paintings and like Halloween things in them. And so, and I live in the Pacific Northwest, which is beautiful. We have a hundred year old cabin on three acres, and it's, it was October. It was just like, stunning. And I was looking out in our, my backyard and I was like, "I wanna paint this." And I just sat down. I mean, I'm not artistic. I've never and it looked like a 8-year-old painted it and my partner Joe was like, "Maybe watch a video." It's great. I love it. But, you know, and so I found, you know, like Bob, apparently all, every episode of Bob Ross was on Netflix at least last year. And so I just started watching some videos and some videos on YouTube, and I started getting better and better pretty quickly. Like I, you know, I started, you know, little tutorials here and there. And then I realized, like I was also reading books to help me kind of get in this entrepreneurial mindset like growth mindset or "Mindset" by Carol Dweck, which talks about growth mindset. And I realized like, you can teach yourself to do anything. Like I had told myself for the longest time, I mean, I started my I'm 40 and so I told myself for 40 years, like, "I'm not artistic." That was my box I painted around myself. And then all of a sudden I was like, "Well, let's give it a shot." And so, you know, there's, I realize like you set these boundaries in your parameters in your head and you blow them up a little bit. Like, you know what? Like, let's just see, let's try you know, and I see this with our teenagers too, it's sometimes like when they struggle in school, they'll be like, "I'm not smart, or I'm not this." And I'm like, "You just have to try." Like anything worth doing takes effort. And if everybody quit because they weren't good. The first time or even like the 10th time, like imagine how little progress we would make as a society. So I think if something you wanna do something recognizing, like you can learn to do it. And I think that also helped ignite, like me knowing I could be, do my consulting company and really launch it. And so I just started reaching out to people who had done it and I hired coaches and I started to learn more about what would make it work and what I would need to do. And you know what a novel idea, right? You find the person who's doing what you wanna do and you learn from them. You know, and it's just like that entire journey over the last year was really helpful to, I think, get me to the head place like I needed to be, to like leave the safety of a W2 job and launch a company. Just to like lie, you know, to myself every, and be like, "You can do it." Because, you know, if you start every day with the, "I don't know if this is gonna work," like I, there's no way I would've done this. I really had to tell myself I could do it, it was gonna work, and I realized now that I've gotten past that, it's very harder like to put a boundary around me now. Like now it's a challenge, right? Like if you tell me I can't do something, I'm like, "Oh, let's see." I bet you, you know, even if I'll fail, like the first few times, I want to try to see if I can do it because I now have this delusion that I can teach myself to do just about anything, so. [00:28:18] Lindsey Dinneen: That's awesome. [00:28:20] Logan McKnight: Or not. [00:28:20] Lindsey Dinneen: Yeah, no, that is incredible. And you're absolutely right. I think we can all relate to, at least in some element of our lives, painting boxes around ourselves and going, "I'm not this," or "I'm not that," or "I'll never get to be able to do this. I'll never be proficient." And those things aren't true. It's just what we tell ourselves. So I love the fact that painting opened up those doors for you. [00:28:43] Logan McKnight: Yeah. No it's so true. And I think it's like a. You know, a metaphor for life. And I think I hear that a lot of times from people will be like, "I wish I could do what you," and I'm like, " You can literally do anything." That's how crazy. And, you know, we're in peak New Year's resolution time, right? And I think a lot of people are like, "Oh, I wanna do this and do that." And that's like, you can, you just like, if you wanna be a person that exercises more. Just go start exercising. That's how wild the world, like our brains can make us do whatever we want. So anyway, I'm also a big psychology buff 'cause I, I'm a big believer in like the power of the human brain and what it can do over your decision making and your life and the impact it can have, you know, everything really. [00:29:27] Lindsey Dinneen: Yeah. No, absolutely. Yeah, I couldn't agree more. I love that perspective and yeah, growth mindset is a wonderful gift because, you know, you can explore, you can try, and as long as you're sticking with it and doing those things, then you're not failing. You're just, you're just exploring and then you can just keep exploring and find things that are right for you. And you know, not everything will stick, and that's okay too, so. [00:29:55] Logan McKnight: Yeah, a hundred percent. Yeah. I always tell people "I'm still figuring what I, or figuring out what I wanna do when I grow up." You know, and I think that's an ongoing thing, and I hope when I'm 80, I still am figuring out like what's next. [00:30:06] Lindsey Dinneen: Yeah. [00:30:07] Logan McKnight: It's exciting. So. [00:30:08] Lindsey Dinneen: Yeah. All right, well pivoting the conversation a little bit just for fun. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. It could be within your industry, but it doesn't have to be. What would you choose to teach? [00:30:24] Logan McKnight: You know, I think this, it ends up being the thing I talk about most. And it's the thing I think I wanted to do initially, but it was really a struggle to just target and talk to managers, especially like frontline managers. But I think that transition from being an independent contributor to becoming a first time leader-- like if I could teach a masterclass in that, I think that would be really fun. I see so many very empathetic and like capable independent contributors, whether they be like rockstar sales rep or even a great like technologist or engineer. And then they were like, "Okay, well I need to move up the ladder. I'm gonna be a people manager," and then their next step is people management. And they're like, "This sucks. Like I, nobody told me about like all the things I have to deal with and the people." And you're still in the mindset of like box checking, of like, in order to be successful, "I have to do all these things. I have to do X, Y, and Z." And I think that the second I stopped checking all the boxes and trying to do all the things was when I went from being like a manager to an actual leader of people and activating them. And if I could just get a few people who I believe, like I've even seen so many really great people leave the industry because they feel like they want to advance, but they don't see because they weren't a good manager, like, "Well, how would I ever be a good director or a good VP," or so on and so forth. The reality is like probably the hardest transition is going from independent contributor to a manager, and yet it's like the least supported space. So that's I think that's something I feel deeply passionate about and would love to like able to offer as a resource more for people. [00:32:10] Lindsey Dinneen: And that would be an incredible masterclass. Okay, and then how do you wish to be remembered after you leave this world? [00:32:18] Logan McKnight: I love that one. I mean, I think at the end of the day, that's the impact thing. You know, and I don't even think it has to be this, like, big, you know, like, "Oh, I, you know, solved healthcare in Ghana." Like, you know, it's not that. It's almost like I, I hope that like my company and my interaction with people leaves everyone feeling a little lighter, a little happier, like a little more capable to do like something, and they feel like talking with me, working with me has unlocked like the next level of something that they've been struggling with and makes them feel like, "Okay, I can do this now." 'Cause I almost feel like that's what, what coaching and consulting comes down to is I'm not doing the thing for anybody. I am only helping to remove the roadblock around them, that they stop limiting themselves and they really see what's possible just by making a few changes in the way they think, in the way they operate their business or run their team. And, you know, amazing things happen. So my hope is that I just continue to get to do that and have people that really feel positive impact from that. [00:33:26] Lindsey Dinneen: Yeah. Well that is a beautiful legacy, so, yeah. All right. And then final question. What is one thing that makes you smile every time you see or think about it? [00:33:38] Logan McKnight: Oh, gosh. Well, we just talked about this before our call, but my dog, I have, I'm an animal lover, and so I have the fortune that every day, most every day I'm in my home office and I get to go on a hike or walk with my dogs, either around our property or out somewhere in beautiful Washington. And I think just like seeing the mountains and being out with my dog, like that just makes me smile. And I think it's also what inspired me to paint and all the things. So I, I think just all the beauty like in the world just makes me smile and makes my heart very happy. [00:34:12] Lindsey Dinneen: I love that. Oh my goodness. That's beautiful. All right, well this has been an amazing conversation, Logan. I so appreciate you and your time today. And we're so honored to be making a donation on your behalf as a thank you for your time today to the American Society for the Prevention of Cruelty to Animals, which is dedicated to preventing animal cruelty in the United States. So thank you for choosing that organization to support and we just wish you continued success as you work to change lives for a better world. [00:34:43] Logan McKnight: Yeah, thanks for having me. We'll talk soon. [00:34:45] Lindsey Dinneen: Sounds good. Thank you and take care. [00:34:49] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of developments that highlight the dynamism and complexity of our industry. The pharmaceutical and biotech sectors continue to evolve rapidly, driven by scientific innovations, regulatory shifts, and strategic initiatives.Eli Lilly's recent move to launch "Employer Connect," a platform aimed at improving access to its obesity medications, marks a significant step in addressing the growing public health issue of obesity. This initiative reflects the increasing influence of employer-driven healthcare solutions in managing chronic conditions. By directly involving employers, Eli Lilly seeks to enhance both the accessibility and affordability of its treatments, which could lead to better patient outcomes and reduced healthcare costs associated with obesity-related complications.In dermatology, Galderma has doubled its sales projections for Nemluvio (nemolizumab), an atopic dermatitis treatment, following a successful market debut. The revised projection to over $4 billion in peak annual sales underscores Nemluvio's strong market performance against competitors like Dupixent. This success not only highlights the drug's therapeutic efficacy but also indicates robust market demand for innovative dermatological therapies.Regulatory landscapes remain pivotal in shaping the industry. Vanda Pharmaceuticals' ongoing efforts to expand Hetlioz's label for jet lag treatment have been met with regulatory challenges since 2019. The FDA's response to Vanda's request for a public hearing underscores the complexities involved in navigating approval processes for label expansions. The outcome of such hearings could have broader implications for similar drugs seeking label amendments.Geopolitical dynamics also influence biopharma investments, with Ireland emerging as a stable manufacturing hub amidst global uncertainties. Despite geopolitical tensions, U.S. investments continue to flow into Ireland, highlighting its strategic importance as a location for biopharmaceutical manufacturing and innovation.In oncology, Pfizer is advancing its research and development strategy under Jeff Legos' leadership by leveraging its $43 billion acquisition of Seagen. The aim is to build an antibody-drug conjugate empire while advancing a PD-1xVEGF bispecific drug licensed from 3SBio. This approach underscores Pfizer's commitment to expanding its oncology pipeline through innovative therapies and combination regimens that could potentially transform cancer treatment paradigms.Meanwhile, Merck KGaA faces challenges with declining U.S. sales of Mavenclad due to anticipated generic competition. This situation reflects a broader industry trend where pharmaceutical companies must navigate patent expirations and generic market entries that threaten revenue streams of established products.Leo Pharma's launch of a direct-to-consumer campaign for Anzupgo, targeting hand eczema treatment, signifies the growing role of consumer engagement in pharmaceutical marketing strategies. Such approaches are becoming increasingly important in reaching patients directly.Collaborations remain a key driver of innovation within the industry. Daiichi Sankyo's partnership with German medtech Gaia to commercialize Lipodia—a digital therapeutic for high cholesterol management—illustrates the convergence between digital health technologies and traditional pharmaceuticals.In gene therapy news, uniQure finds itself in a contentious dialogue with the FDA over its Huntington's disease therapy. The debate centers around uniQure's claim that the FDA requested a "sham trial," which the agency denies. This situation underscores regulatory complexities surrounding gene therapies targeting rare diseases.Simultaneously, PepGen faces a partial clinical hold on its muscle wasSupport the show
Check out host Bidemi Ologunde's new show: The Work Ethic Podcast, available on Spotify and Apple Podcasts.Email: bidemiologunde@gmail.comIn this episode, host Bidemi Ologunde sits down with JoJo Kalita, Vice President of Partnerships and ACTOverse at ACTO. JoJo is a tech leader with over a decade of experience across Operations, Customer Success, and now Partnerships, where she's helping shape the AI landscape through collaborations with global industry leaders, including work in life sciences and beyond. How do you build operational systems that drive efficiency without losing the human touch? What does "customer obsession" look like when your job is no longer customer-facing, but partnership-driven? And how can emotional intelligence turn mentorship into a ripple effect of real impact? JoJo shares the lessons behind her relationship-first leadership style, her approach to choosing the right partners, and how to leverage technology in ways that stay grounded in empathy, clarity, and outcomes.Sponsors and partners:Promeed: 100% mulberry silk pillowcases and bedding that feel incredibly soft, stay breathable, and are naturally gentle on hair and skin.SurviveX: professional-grade FSA/HSA eligible first aid and preparedness kits designed in Virginia, USA and produced in an FDA-registered facility.Alison US CA: Alison is the world's largest free online learning and skills-training platform, helping more than 50 million learners in 193+ countries build career-ready skills with 6,000+ free courses, certificates, and diplomas.eSign (iOS only): eSign is a clean, privacy-first document-signing app that works entirely on your device, letting you sign PDFs, DOCX files, images, and scans, edit and assemble pages, and export crisp 300 DPI PDFs in seconds, without accounts, cloud uploads, or compromising sensitive documents.Support the show
This is a Vintage episode from 2007.Why This Episode MattersBaking isn't magic; it's chemistry. Gail explains ingredient function so you can so you can bake with intention rather than habitLearn how to substitute intelligently (yogurt for buttermilk, butter vs lard, etc.) without sabotaging structure The episode is packed with practical fundamentals: tools, pantry essentials, pie crust fat choices, and why ice cream flavors must be stronger before freezing.The BanterMark Pascal and Francis Schott open with a recap of a “Duckathlon” with other restaurants— assessing steak, cheese, birds, and brandy. They then pivot hard into food-label transparency and why consumers should be allowed to know what's been done to their food.The ConversationGail Sokol joins to explain why baking differs from cooking and what you need to know. She breaks down how acid-base reactions relate to texture and how her book teaches technique. They also get into real-world home baking: what tools matter, what belongs in your pantry, why lard makes flaky crust, and how to make ice cream that doesn't taste flat once frozen. (Caution: May require sampling.)Timestamps0:00 – “Duckathlon” recap: IDing steak, cheese & mystery birds4:40 – FDA labeling debate: transparency vs “choice” rhetoric9:30 – Gail Sokol joins: baking is science, leavening explained17:10 – Why her book teaches methods: visuals, steps, and understanding ingredient roles20:40 – Home baker essentials: mixer, bowls, spatulas, & whisks 24:00 – Pie crust: butter vs lard; why blends work29:40 – Ice cream fundamentals: pre-chilling, flavor “punch,” serving temperatureGuest BioGail Sokol is an award-winning professional baker and college-level baking instructor. She's the author of About Professional Baking: The Essentials, a fundamentals-first baking guide focused on methods, ingredient function, and technique.Show InfoAbout Professional BakingBy Gail SokolGail's site https://chefgailsokol.com/Join us on March 12 for a wine dinner with BallettoClick below for more info:https://www.stageleft.com/event/31226-balleto-winemaker-dinner-w-anthony-beckman/ Become a Restaurant Guys' Regular!https://www.buzzsprout.com/2401692/subscribeMagyar Bankhttps://www.magbank.com/Withum Accounting https://www.withum.com/restaurantOur Places Stage Left Steakhttps://www.stageleft.com/ Catherine Lombardi Restauranthttps://www.catherinelombardi.com/ Stage Left Wineshophttps://www.stageleftwineshop.com/ To hear more about food, wine and the finer things in life:https://www.instagram.com/restaurantguyspodcast/https://www.facebook.com/restaurantguysReach Out to The Guys!TheGuys@restaurantguyspodcast.com**Become a Restaurant Guys Regular and get two bonus episodes per month, bonus content and Regulars Only events.**Click Below!https://www.buzzsprout.com/2401692/subscribe
Cattitude - Cat podcast about cats as pets on Pet Life Radio (PetLifeRadio.com)
On this episode of Cattitude, Michelle Fern welcomes veterinarian Dr. Heather Davis, Director of Clinical Affairs and Veterinary Services for Pegasus, to discuss hypertrophic cardiomyopathy (HCM)—a surprisingly common heart disease that affects about 1 in 7 cats. Often called a silent killer because symptoms can go unnoticed until the disease is advanced, HCM is something every cat parent should know about. Dr. Davis explains what causes HCM, why certain breeds like Maine Coons, Ragdolls, and Sphynx cats may be at higher risk, and how veterinarians diagnose and manage the condition. She also shares a simple “breath test” cat owners can do at home to help detect early warning signs while their cat is sleeping. Plus, Michelle and Dr. Davis discuss new advances in veterinary medicine, FDA-approved treatments for feline heart disease, and the importance of working closely with your veterinarian instead of relying on “Dr. Google.” If you love your cat and want to stay proactive about their health, this informative episode is a must-listen.EPISODE NOTES: The 30-Breath Test That Could Save Your Cat's LifeBecome a supporter of this podcast: https://www.spreaker.com/podcast/cattitude-the-1-cat-podcast--6666768/support.
The founders of Hershey, Good Humor, Stouffer, Heinz, Kellogg, Kraft, and Birdseye, among others, were pioneers looking to bring clean, hygienic, healthy, and trustworthy products to a market saturated with the opposite. Each specialized in a product, be in chocolate, ice cream, prepared meals, ketchup, cereal, cheese, or frozen foods. Recently we have learned that the grandson of the inventor of Reeses's Peanut Butter cups, owned by Hershey today, has accused the company of destroying the original product, changing "milk chocolate" and "peanut butter" to substances that mirror them. Whereas Milton Hershey sourced fresh milk and used minimal ingredients, modern Hershey products are anything but fresh or even what the label implies. Also, at least 111 substances of unknown safety have been added to foods, drinks and supplements sold in the United States without alerting the US Food and Drug Administration, a new investigation found. This is on top of the exposure that has recently been brought to American foods in general, from food coloring to preservatives - leading companies to change their ingredient lists with a promise of never again lying to consumers. What were companies that attempted to bring purity to a contaminated marketplace, largely resulting from overcrowded cities, has turned ironically into the very thing that they were formed to fight. Now under "trusted brands" the foods that poisons Americans a century ago have made a reemergence.*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.
We've had many conversations on Raise the Line about the challenges of health communication in today's world of information overload, but none of our guests have the kind of expertise Dr. Tesfa Alexander has acquired in a career that has taken him from Madison Avenue to the halls of government and academia. From guiding tobacco education research at the FDA to leading public health initiatives at MITRE, Dr. Alexander has developed a deep understanding of the science and strategy behind effective health communication. “Successful campaigns keep the long game in mind where you want to develop a lasting relationship with your target audience,” he tells host Lindsey Smith. That relationship needs to be built on understanding culture, beliefs, priorities and daily realities, and only then can you develop messaging that will resonate, he explains. Dr. Alexander also believes these relationships can be leveraged to help people sort out facts from misleading or inaccurate claims. “I strongly recommend shifting our focus from combating misinformation head on, and instead working with the communities who we are seeking to serve.” This fascinating look at communication science also covers: How stories drive belief; The importance of working with community partners who are trusted messengers; The power of audience segmentation. Tune in as Dr. Alexander unpacks what it takes to influence beliefs, and ultimately behaviors, in an era defined by misinformation and institutional mistrust. Mentioned in this episode:Lerner Center for Public Health Advocacy If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
The global medical device regulatory environment is complex, often requiring manufacturers to repeat similar submissions and audits across multiple countries. This duplication slows innovation and delays patient access to life-saving technologies.To address this challenge, international regulators are increasingly collaborating through the International Medical Device Regulators Forum (IMDRF).In this podcast episode, Stephanie Grassmann (MedTechXperts) joins us to discuss how the concept of Regulatory Reliance is transforming global medical device approvals.What is IMDRF?The International Medical Device Regulators Forum (IMDRF) is a voluntary group of regulatory authorities working together to harmonize medical device regulations and reduce duplication across global markets.Members include major regulatory bodies such as:• United States (FDA)• European Union• Australia (TGA)• Brazil (ANVISA)• Canada (Health Canada)• China (NMPA)Their mission is to promote efficient regulation while maintaining high standards of safety and performance.Understanding Regulatory RelianceRegulatory reliance allows one authority to give significant weight to the work already performed by another trusted regulator.Instead of repeating full assessments, authorities can leverage existing evaluations, reducing regulatory burden while maintaining confidence in safety and effectiveness.Real-World Success StoriesSeveral regulators are already demonstrating the benefits of reliance mechanisms.Australia – TGAA Class III Mitral Valve Clip reached market access in just 20 working days after the regulator accepted evidence generated overseas.Argentina – ANMATDental instruments known as endodontic barbed broaches were approved in 9 working days using reliance pathways.Brazil – ANVISACompanies holding MDSAP certification may skip immediate on-site audits, saving both time and money during market entry.These examples show how regulatory cooperation can significantly accelerate approvals.The Role of MDSAPThe Medical Device Single Audit Program (MDSAP) allows manufacturers to undergo a single regulatory audit recognized by multiple countries.This program plays a key role in enabling reliance between regulatory authorities and reducing redundant inspections.The European PerspectiveEurope has historically maintained a distinct regulatory framework under EU MDR and IVDR.However, recent proposals—including references to Articles 108a and 108b—suggest increasing collaboration with international frameworks such as IMDRF and MDSAP.While a single global approval system remains a long-term goal, reliance initiatives are already demonstrating that cooperation between regulators can improve efficiency without compromising safety.Looking AheadFor manufacturers and startups, embracing international regulatory frameworks early—such as MDSAP and IMDRF guidance—can significantly improve global market access strategies.As regulatory collaboration grows, the future of medical device approvals may become faster, more harmonized, and more patient-centered.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more. If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkStephanie Grassmann Linkedin: https://www.linkedin.com/in/stephaniegrassmann-medtechxperts/Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is powered by Podcastics, the easiest platform to create and publish your podcast.
In this episode of On Rare: Innovators, hosts David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Senior Director of Patient Advocacy at BridgeBio, speak with Kat Bryant Knudson, Founder and CEO of the Speak Foundation and a leader in the limb-girdle muscular dystrophy (LGMD) community. Diagnosed as a child after experiencing early symptoms of muscle breakdown, Kat spent years searching for answers before receiving a definitive genetic diagnosis. What began as a personal journey to understand her condition evolved into a lifelong commitment to ensuring that no one with LGMD faces that journey alone. From founding the Speak Foundation in an unexpected twist of fate to organizing groundbreaking scientific workshops that bring patients, researchers, industry, and the FDA to the same table, Kat has helped reshape how the LGMD community connects, advocates, and advances research. Guided by the belief that people with lived experience should have the loudest voice in the room, Kat continues to innovate on behalf of a diverse and growing rare disease community. Kat's story is a reminder that progress begins with connection, shared experience, and the courage to speak up. Pantene is a third-party trademark. BridgeBio is not affiliated with or endorsed by Pantene or Procter & Gamble, and this reference is for storytelling purposes only.
How solid is your CMC foundation—and what happens if it cracks under pressure?David Brühlmann welcomes Henri Kornmann, former Head of Biologics Innovation Centre at Ferring Pharmaceuticals. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has moved repeatedly between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs.His “house building” approach demystifies CMC's complexity, showing why early diligence paired with regulatory fluency and scientific insight pays dividends for years.Tune in to hear Henri's practical wisdom distilled through real-world analogies:Building a strong CMC foundation in early phases and why later fixes can be costly or impossible (02:45)Scaling up: supplying Phase 3 with the final commercial process, including robustness and supply chain strategies such as dual sourcing critical raw materials (03:23)Process validation explained: FDA's three stages, from control strategy justification to continued verification (05:15)Process Performance Qualification (PPQ): what it is, how many batches are needed, and optimizing timing (07:43)Handling lifecycle changes: maintaining process control, adapting to deviations, and improving systems after regulatory approval (09:34)Managing teams, stakeholders, and cross-functional collaboration in CMC programs (11:49)Importance of good project management, access to scientific expertise, and interpreting guidelines for your specific program (12:27)The “half scientist, half lawyer” analogy for mastering both technical and regulatory aspects (15:08)Smart insight:Never underestimate CMC. If you do, you will pay for it later.If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC DevelopmentEpisodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeEpisodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerConnect with Henri Kornmann:LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Dr. Steven St. Peter, Co-Founder and Managing Director of Vie Ventures, discusses his firm's unique hybrid model that combines venture capital with disease philanthropy to accelerate the development of new therapies for autoimmune diseases. While philanthropies have excelled at funding basic research, a gap exists in translating those findings into FDA-approved drugs. Steven points out that the autoimmune field is entering a golden age, driven by insights from immuno-oncology and by AI's potential to analyze data across autoimmune diseases. Steven explains, "I've been doing venture capital for the last 30 years. I'm also a physician, but I'm very interested in how venture capital is helping bring new therapies to patients, and that's really the core of what venture capital does. So I've been doing that and am comfortable with that for a long time, as well as my co-founders. About five years ago, I joined an effort working with the disease philanthropy to help create a hybrid model. And I thought that was very interesting because these disease philanthropies are really the voice of the patient. So to the extent that you can bring disease, philanthropy, and venture capital to mix, I just think that's an incredible model, and that really is what Vie Ventures is all about." "The large disease-focused philanthropies have done a phenomenal job in funding basic science research coming out of academics and helping really define, well, what is autoimmune disease and what are the biological systems and why does that matter? And in fact, just taking the case of type 1 diabetes until the 1980s, we didn't even know that that was an autoimmune disease. And in an autoimmune disease, it's the body's immune system attacking a tissue that it shouldn't. And the consequence is that it manifests as a sort of disease. So a lot of the research foundation spent a good amount of time teasing out all that basic science, and that led to insights that then allow us to create new therapies to actually change the course of these diseases. And so as you roll the clock forward to where we are in 2026, that biology has been defined." "So what Vie Ventures does is it really allows a way for these disease foundations to reach into the translation of that fundamental discovery research to actually fund drugs that are going into patients to hopefully result in an FDA approval. And that just hasn't been done in the past because the science hadn't been defined yet, but now we're at this very exciting time, and that's the next frontier." #VieVentures #AutoimmuneDisease #VentureCapital #CARTTherapy #Immunology #PatientAdvocacy #Biotech #HealthcareInnovation #Type1Diabetes #MultipleSclerosis #Lupus #EmpoweredPatient #HealthcarePodcast #MedicalResearch #PatientCentricity #DiseasePhilanthropy #AutoimmuneDisorders #ImmuneOncology #VentureImpact vieventures.com Download the transcript here
Dr. Steven St. Peter, Co-Founder and Managing Director of Vie Ventures, discusses his firm's unique hybrid model that combines venture capital with disease philanthropy to accelerate the development of new therapies for autoimmune diseases. While philanthropies have excelled at funding basic research, a gap exists in translating those findings into FDA-approved drugs. Steven points out that the autoimmune field is entering a golden age, driven by insights from immuno-oncology and by AI's potential to analyze data across autoimmune diseases. Steven explains, "I've been doing venture capital for the last 30 years. I'm also a physician, but I'm very interested in how venture capital is helping bring new therapies to patients, and that's really the core of what venture capital does. So I've been doing that and am comfortable with that for a long time, as well as my co-founders. About five years ago, I joined an effort working with the disease philanthropy to help create a hybrid model. And I thought that was very interesting because these disease philanthropies are really the voice of the patient. So to the extent that you can bring disease, philanthropy, and venture capital to mix, I just think that's an incredible model, and that really is what Vie Ventures is all about." "The large disease-focused philanthropies have done a phenomenal job in funding basic science research coming out of academics and helping really define, well, what is autoimmune disease and what are the biological systems and why does that matter? And in fact, just taking the case of type 1 diabetes until the 1980s, we didn't even know that that was an autoimmune disease. And in an autoimmune disease, it's the body's immune system attacking a tissue that it shouldn't. And the consequence is that it manifests as a sort of disease. So a lot of the research foundation spent a good amount of time teasing out all that basic science, and that led to insights that then allow us to create new therapies to actually change the course of these diseases. And so as you roll the clock forward to where we are in 2026, that biology has been defined." "So what Vie Ventures does is it really allows a way for these disease foundations to reach into the translation of that fundamental discovery research to actually fund drugs that are going into patients to hopefully result in an FDA approval. And that just hasn't been done in the past because the science hadn't been defined yet, but now we're at this very exciting time, and that's the next frontier." #VieVentures #AutoimmuneDisease #VentureCapital #CARTTherapy #Immunology #PatientAdvocacy #Biotech #HealthcareInnovation #Type1Diabetes #MultipleSclerosis #Lupus #EmpoweredPatient #HealthcarePodcast #MedicalResearch #PatientCentricity #DiseasePhilanthropy #AutoimmuneDisorders #ImmuneOncology #VentureImpact vieventures.com Listen to the podcast here
For decades, midlife has been framed as a time of decline for women — medically, culturally, and personally. Halle Berry is on a mission to change that. On this episode of The Dr. Hyman Show, she shares how her own menopause journey exposed how little real support exists for the 60 million women navigating this transition. That experience ultimately led her to create ReSpin, the community she couldn't find when she needed it. Watch the full conversation on YouTube or listen wherever you get your podcasts. We discuss: • Why menopause is often missed — and how to take back control of your energy, mood, and metabolism • What changes in your brain, bones, and muscle and how to protect them in midlife • How comprehensive testing gives you a personalized roadmap for this phase of life • Why fatigue, low libido, and brain fog aren't “just aging” — and what improves when you address the root cause Your second act can be your strongest. It's a chance to reclaim your strength, your energy, and your future on your own terms. This conversation was recorded live at the Eudēmonia Summit. View Show Notes From This Episode Get Free Weekly Health Tips from Dr. Hyman https://drhyman.com/pages/picks?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Sign Up for Dr. Hyman's Weekly Longevity Journal https://drhyman.com/pages/longevity?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Join the 10-Day Detox to Reset Your Health https://drhyman.com/pages/10-day-detoxJoin the Hyman Hive for Expert Support and Real Results https://drhyman.com/pages/hyman-hive This episode is brought to you by Seed, BIOptimizers, PerfectAmino, BON CHARGE, Made In Cookware and Maui Nui. Go to seed.com/hyman and use code 20HYMAN to get 20% off your first month. Head to bioptimizers.com/hyman and use promo code HYMAN at checkout to save 15%. Go to bodyhealth.com and use code HYMAN20 to get 20% off your first order. Upgrade your routine. Head to boncharge.com/hyman and use code HYMAN for 15% off. Head to madeincookware.com and use the code DRHYMAN for 10% off your order. Learn more about the health benefits of venison and how to get yours, head over to mauinuivenison.com/hyman. (0:00) Halle Berry's health journey and the overlooked issue of menopause (1:21) Introduction to the Eudaimonia Summit (3:27) Women's health problems: Causes and personal stories (7:12) Misdiagnosis, confusion, and the mission to educate (10:01) Women's Health Initiative study and FDA updates (12:48) Hormone therapy and perimenopause symptoms (17:22) Lifestyle's role in hormonal health and disease prevention (22:12) Alcohol, nicotine, and long-term health risks like Alzheimer's (25:26) Early hormone replacement therapy and personalized care (28:15) Sexual health discussions and Halle Berry's ReSpin initiative (32:22) Cultural change, low-tox living, and structural health in menopause (37:01) Menopause symptoms variability and addressing health disparities (39:52) The need for medical education reform and JoyLux's contribution (41:12) Psychedelics in mental health treatment (43:43) Closing remarks and listener engagement (44:00) Disclaimer about podcast content
On today's episode, Andy travels to Austin to visit with Ways2Well founder Brigham Buhler at his Longevity Lab lab to discuss the search for the genetics secrets to eliminating chronic disease and how some species seem to live forever. They dig into why how the field is practiced today often leave patients without real answers, and why Buhler believes a more preventative, patient-focused approach could change that. Change Agents is an IRONCLAD Original Chapters: (00:00) Intro (02:08) Redesigning the Clinic: Making Healthcare Fun (07:10) How Insurance & PBMs Broke the Medical System (14:42) Big Pharma's War on Compounding & Telemedicine (18:22) Why Your Doctor Is Trapped in a Broken System (21:18) Ways2Well Tour: 80s Nostalgia & UV Murals (30:52) The Opioid Crisis & Brigham's Origin Story (38:25) Fighting the FDA & The Illusion of Surgical Safety (43:47) What Are Peptides & Why Pharma Wants Them (48:22) ALLEN: The Ways2Well AI Health Assistant (52:14) Debunking Medical Myths: Testosterone & HRT (58:16) Wearables & The Future of Proactive Health (01:10:57) Inside the Lab: Stem Cells, Red Light, & Hyperbaric Oxygen (01:17:48) Next-Level Detox: Blood Filtration (IBU) & Ozone Saunas (01:20:25) Gene Editing & The Future of Human Evolution Sponsors: Firecracker Farm Use code IRONCLAD to get 15% off your first order at https://firecracker.farm/ GHOSTBED: Go to https://www.GhostBed.com/IRONCLAD and use code IRONCLAD for an extra 15% off sitewide. Subscribe on Apple Podcasts: https://podcasts.apple.com/us/podcast/change-agents-with-andy-stumpf/id1677415740 Subscribe on Spotify: https://open.spotify.com/show/3SKmtN55V2AGbzHDo34DHI?si=5aefbba9abc844ed Learn more about your ad choices. Visit megaphone.fm/adchoices
On this episode of Vitality Radio, Jared sits down with Roz Marchant, founder of Hair's A Million, to explore the surprising story behind a natural hair health breakthrough. After losing her hair during cancer treatment, Roz began researching nutrient-dense, toxin-free ingredients that could support healthy hair and scalp function. What started as a personal experiment eventually became a widely used hair serum developed with a focus on clean ingredients and topical nutrition. Jared also shares the science behind his Hair Revive formula, created to address common internal factors linked to hair thinning such as nutrient depletion, stress, and hormonal shifts. Together they discuss the inside-out approach to supporting hair health, how lifestyle and nutrient status may influence hair growth cycles, and why ingredient integrity matters in both supplements and personal care products. If you're interested in natural strategies that support stronger, fuller, healthier hair, this episode is packed with insights.Products:Hairs a Million ProductsRidgecrest Herbals Hair ReviveBuy Hairs a Million Nutrient Infused Hair Serum AND Ridgecrest Herbals Hair Revive and get $20 off (for 30 days from air date)Thyme Out (Vitality Radio POW! Product of the Week 25% off with PROMO CODE: POW30)Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
About the Guest(s): Dr. Chad Woolner is a chiropractic physician who brings a wealth of knowledge and experience in utilizing advanced technologies to enhance patient care and wellness, including the use of laser and light-based therapies. Dr. Woolner has established himself as a credible voice in chiropractic care and is widely recognized for his expertise in integrating innovative treatments. Dr. Andrew Wells is an accomplished expert in natural health solutions, with a strong focus on the synergy between technology and healthcare. He collaborates closely with Dr. Woolner in providing insights into effective health practices, including weight loss strategies through cutting-edge light-based therapies. Episode Summary: In this engaging episode of the Laser Light Show, Dr. Chad Woolner and Dr. Andrew Wells discuss ground-breaking developments in light-based therapies, specifically focusing on weight and fat loss. The conversation revolves around Erchonia's latest technological advancements that promise to transform traditional approaches towards managing obesity and promoting healthier lifestyles. They introduce the new Zerona Z8 laser—an FDA-cleared, high-intensity violet laser designed to increase cellular energy and stimulate weight loss, offering new hope and tools for both individuals and practitioners. The episode delves into the rising challenges and perceptions surrounding obesity, weight loss interventions, and the growing popularity of GLP-1 medications. It highlights the importance of integrating tools like Zerona lasers with holistic lifestyle changes for a sustainable weight loss solution. Dr. Woolner and Dr. Wells stress the critical role of cellular energy in weight management and how addressing mitochondrial dysfunction can mitigate the obesity epidemic facing many. They advocate for an energy-first approach that prioritizes physiological health to facilitate consistent long-term behavioral shifts in diet and exercise regimens, ultimately fostering a more balanced and sustainable lifestyle. Key Takeaways: Light-based therapies, like the new Zerona Z8 laser, can revolutionize weight loss treatments by enhancing cellular energy and supporting long-term lifestyle changes. Chronic health issues and weight management difficulties often stem from insufficient cellular energy, making it essential to address mitochondrial dysfunction. The popular notion of light therapies as quick-fixes for melting fat fails to capture the full potential of these technologies as catalysts for broader health improvements. Incorporating tools like lasers with lifestyle adjustments, such as breath work and optimizing circadian rhythms, provides a comprehensive approach to weight loss. A successful weight loss strategy intertwines modern technological interventions with patient dedication to lifestyle changes, offering both immediate and enduring health benefits. Notable Quotes: "The paradigm shift with light-based therapies isn't just about melting away fat, but how they can act as a catalyst for sustainable energy and behavior change." - Dr. Chad Woolner "Patients often lack the physiological energy needed to make lasting lifestyle changes, and that's where therapies like the Zerona laser play a crucial role." - Dr. Andrew Wells "It's about solving mitochondrial dysfunction to empower and enable individuals to make healthier choices consistently." - Dr. Chad Woolner "When you increase your body's capacity to produce more energy, it not only supports weight loss but overall wellness and quality of life." - Dr. Andrew Wells "Using the Zerona laser as a catalyst can completely change someone's energy and mindset, paving the way for long-term health benefits." - Dr. Chad Woolner Resources: Erchonia's Zerona Lasers Book: Brain Energy by Dr. Chris Palmer Dr. Andrew Huberman podcast on circadian rhythm Enhance your understanding of cutting-edge weight loss technologies by listening in on this enlightening episode. Stay tuned for more insights from Dr. Chad Woolner and Dr. Andrew Wells on the Laser Light Show, revealing how innovative therapies and holistic approaches can transform health practices.
Most conversations about “AI in Medicine” bore me. I think this is because either we lack the imagination to consider how AI will change medicine in the next decade, or we are not being specific enough about how small parts of medicine could be productively affected.Dr. Shantanu Nundy, MD, MBA, is a practicing physician whom I like to think of as a serial innovator. He is currently an advisor on artificial intelligence to the FDA in the Commissioner's Office. He has spent a great deal of time and energy thinking deeply about what AI can bring us today and in the future. I hope you enjoy this conversation. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe
March 4, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Quest Diagnostics unveils AI chatbot in MyQuest portal analyzing five years of lab data powered by Google's Gemini models Subco launches independent supplement certification program anonymously purchasing retail supplements and verifying ingredients in independent labs Eight Sleep raises funding at $1.5B valuation, shifting from reactive sleep optimization to predictive AI agent and pursuing FDA clearance for sleep apnea detection More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co
Elevance Health's Medicare Advantage plans face federal sanctions. The University of Mississippi Medical Center clinics reopen after a ransomware attack. And the FDA warns telehealth companies about marketing compounded weight loss drugs. That's coming up on today's episode of The Gist Healthcare Podcast. Hosted on Acast. See acast.com/privacy for more information.
In this edition of Essential, we look at two major issues facing pharmacy compounding. First is a state-by-state effort by pharma companies to pass laws restricting compounding, and second is a cryptic statement from the FDA about possible limitations on compounding with GLP-1 ingredients. They're both Very Big Deals for pharmacists across the country. Links FDA statement on GLP-1 drugs: https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs … and APC's response: https://a4pc.org/news/apc-responds-to-fdas-glp-1-statement Stay up to date on our state Compounding Defense Initiative: compounding.com Join APC today: https://a4pc.org/membership Find us on social: LinkedIn: https://www.linkedin.com/company/a4pcrx/ Facebook: https://www.facebook.com/a4pcrx/ Instagram: https://www.instagram.com/a4pcrx/
In this week's episode of Medicine: The Truth, hosts Jeremy Corr and Dr. Robert Pearl unpack a wide range of developments shaping healthcare in America today, including the TrumpRx drug discount program. From new legislation affecting telehealth and pharmacy benefit managers (PBMs) to the rapid spread of measles and growing public concern about vaccine policy, this month's discussion highlights the policy decisions and scientific debates influencing medicine right now. The episode opens with the latest federal legislation passed to avert a government shutdown. While healthcare was not the central focus of this particular political battle, the bill contains several provisions that affect medical practice. These include extensions for telehealth coverage and hospital-at-home programs, reforms targeting PBM transparency and new requirements designed to address “ghost networks” in Medicare Advantage provider directories. Dr. Pearl explains that while these provisions represent incremental progress, they are unlikely to solve the larger problems driving healthcare costs and access challenges in the United States. Here are the other major storylines from episode 104: Healthcare costs remain nation's top concern: A new KFF poll finds that healthcare expenses rank above food, housing and utilities as the economic issue Americans worry about most. Prior authorization frustrations grow: Many patients report delays or denials of care due to insurance requirements, highlighting persistent tension between insurers, physicians and patients. Drug pricing debates continue: Pearl examines a new prescription drug website initiative and explains why it may have limited impact compared with broader policy proposals such as “most favored nation” pricing. Telehealth's uncertain future: Although the latest legislation extends certain pandemic-era flexibilities, the lack of a permanent solution leaves virtual care programs in limbo. PBM reforms move forward slowly: New policies aim to increase transparency and reduce incentives tied to drug list prices, though Pearl notes that meaningful change will depend on future implementation. Site-neutral payment gains attention: A provision requiring unique identifiers for outpatient services could pave the way for policies that eliminate higher reimbursement for hospital-owned facilities providing identical care. Measles outbreaks surge: Nearly a thousand cases have already been reported in 2026, with the overwhelming majority occurring among unvaccinated children. Trust in the CDC declines: Polling shows confidence in the agency has dropped significantly following changes to vaccine recommendations. Independent vaccine review groups emerge: Medical organizations and states are forming new committees to evaluate vaccine evidence as federal guidance becomes more contested. Early colon cancer deaths rise: The death of actor James Van Der Beek at age 48 highlights the growing incidence of colorectal cancer among younger adults and the importance of earlier screening. FDA confusion over a new flu vaccine: The agency initially declined to review Moderna's mRNA-based flu vaccine before reversing course and agreeing to evaluate it ahead of the next flu season. Younger Americans face worsening health trends: New claims data suggest chronic disease is appearing earlier among millennials and Gen Z, driven by lifestyle factors and reduced connection to primary care. Wearable data reveal health disparities: Apple Watch data show significant differences in resting heart rates across states, reflecting variations in lifestyle, access to care and public health conditions. As the episode concludes, Dr. Pearl warns that growing political conflict around vaccines and biomedical research risks undermining public trust in science. The consequences, he argues, could shape American medicine for decades to come. Tune in for more fact-based analysis and discussion of the biggest stories in healthcare. * * * Dr. Robert Pearl is the author of the new book “ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine” about the impact of AI on the future of medicine. Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on Twitter and LinkedIn The post MTT #104: TrumpRx, rising measles cases & the politics of vaccine science appeared first on Fixing Healthcare.
Squid Game the Challenge News: These reality stars will be the VIP's in the next season! Savannah Chrisley in trouble with the FDA over her GLP-1s; Where has Anya Taylor Joy been? One Star Reviews; The Five Second rule game!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Check out host Bidemi Ologunde's new show: The Work Ethic Podcast, available on Spotify and Apple Podcasts.Email: bidemiologunde@gmail.comIn this episode, host Bidemi Ologunde connects the dots between three fast-moving signals from Feb 23–Mar 1, 2026: a chokepoint-driven escalation in the US/Israel/Iran war, Europe's shift from "paper sanctions" to physical interdictions at sea, and the growing reality that grids and courtrooms are now battlegrounds. What does it mean when the Strait of Hormuz becomes a frontline? Are maritime seizures the new normal in sanctions enforcement, and what happens when states push back in the gray zone? Can international law and infrastructure strikes reshape alliances faster than diplomats can react? Plus: what should listeners watch next as markets, militaries, and legal institutions collide in real time?On the Bid Picture Podcast, I talk about big ideas, and Lembrih is one of them. Born from Ghanaian roots, Lembrih is building an ethical marketplace for Black and African artisans: makers of heritage-rich products often overlooked online. The vision is simple: shop consciously, empower communities, and share the stories behind the craft. Lembrih is live on Kickstarter now, and your pledge helps build the platform. Visit lembrih.com, or search “Lembrih” on Kickstarter.Sponsors and partners:Promeed: 100% mulberry silk pillowcases and bedding that feel incredibly soft, stay breathable, and are naturally gentle on hair and skin.SurviveX: professional-grade FSA/HSA eligible first aid and preparedness kits designed in Virginia, USA and produced in an FDA-registered facility.Support the show
Want deeper support? Join Circle at holplus.co/circle and use code PODCAST for a one-month trial.Hormone therapy is often framed in extremes. It is either dangerous and cancer-causing, or it is the miracle solution to aging. For decades, women have been told to fear estrogen, avoid progesterone, and accept midlife decline as inevitable. But what if the story around hormones was shaped more by panic and oversimplified data than by the full clinical picture?In this episode of hol+, Dr. Taz sits down with preventive medicine pioneer Dr. Erika Schwartz to revisit the Women's Health Initiative and the ripple effects that followed. Together, they explore how one study reshaped hormone replacement therapy guidelines, why the concept of “class effect” blurred important distinctions between different types of hormones, and how relative risk statistics can be misunderstood in ways that drive fear-based decisions.They also discuss bioidentical hormone therapy, the difference between compounded and FDA-approved options, and how delivery methods like creams, patches, and pellets may affect long-term outcomes. The conversation expands beyond menopause into birth control, progesterone deficiency, teen hormone health, and the broader question of how women can advocate for themselves in a system that often prioritizes protocols over personalization.Rather than promoting blind trust or blanket rejection, this episode focuses on clarity. It invites listeners to understand risk more accurately, ask better questions, and approach hormone care with nuance instead of fear. This conversation is for anyone navigating perimenopause, menopause, hormone therapy decisions, or simply wanting to better understand how women's health became so complicated.About Dr. Erika Schwartz Dr. Erika Schwartz is a board-certified internist and a leading voice in preventive and integrative medicine. After spending 15 years practicing conventional medicine and running a trauma center, she shifted her focus toward prevention, longevity, and personalized hormone therapy.For more than three decades, Dr. Schwartz has advocated for bioidentical hormones and individualized care, teaching physicians, speaking internationally, and helping patients navigate midlife health with a whole-body approach. She founded one of the first compounding hormone pharmacies in New York and has worked extensively in physician education through organizations focused on longevity and preventive medicine.She is the author of multiple bestselling books, including the newly revised edition of Don't Let Your Doctor Kill You, which empowers patients to understand medical risk, advocate for themselves, and make informed decisions without fear.Order the BookDon't Let Your Doctor Kill YouStay Connected:Connect further to Hol+ at https://holplus.co/- Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+.Follow Dr. Erika SchwartzInstagram: https://www.instagram.com/drerikaschwartz YouTube: https://www.youtube.com/@DrErika Website: https://drerika.com/Follow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Subscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsGet your copy of The Hormone Shift: Balance Your Body and Thrive Through Midlife and MenopauseHost & Production TeamHost: Dr. Taz; Produced by ClipGrowth.com (Producer: Pat Gostek)
The Middle East faces a major geopolitical shift following a joint U.S. and Israeli operation in Iran that resulted in the death of Supreme Leader Ayatollah Ali Khamenei and several top commanders. President Trump ordered the strike with the goal of "giving the country back to the Iranian people," sparking debate in Washington over executive authority and the War Powers Act. Texas Republican Congressman Pat Fallon, a member of the Armed Services and Intelligence Committees, joins the Rundown to discuss the strategic implications of the attack, and the risk of retaliation at home. With 30 million Americans living with a rare disease, is the traditional "blockbuster" drug model failing the approximately one in 11 people who need specialized care? Judy Stecker, founder of Wheeler's Warriors and former HHS official, joins us to discuss a historic shift at the FDA. From the groundbreaking use of genome editing to treat metabolic diseases to the emotional journey of her son Wheeler, Stecker explains how she believes the science of "genetic patches" has finally outpaced our regulatory system. Plus, commentary by Senior Fellow at the Lexington Institute, Dr. Rebecca Grant. Learn more about your ad choices. Visit podcastchoices.com/adchoices
It's Endometriosis Awareness Month. Ali's guest this week, Holly Abel, was eleven years old when her debilitating periods started. For decades, doctors told her it was “normal.” That she was dramatic. Hormonal. Sensitive. It wasn't normal. In early 2023, Holly was finally diagnosed with severe stage 4 endometriosis — affecting multiple organs throughout her body. Shortly after, she experienced a miscarriage. In December 2023, she underwent major surgery. Then in March 2024, after a routine HSG, everything began to unravel. By early May, she was in septic shock and given a 10% chance to live. In July, a total hysterectomy saved her life… and ended her ability to carry children. Holly talks about all of this and more in an educational, emotional episode about medical trauma, advocacy and survival. EPISODE SPONSORS: THE WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe 3-book bundle is now just $49 (normally $79)!The latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.PHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Go to PherDal.com today and use code INFERTILEAF for $10 off.BELIIG: @belibabywww.belibaby.com Are you thinking about growing your family? Whether you're just starting to plan or are actively trying to conceive, preconception health is key. Beli has vitamins to help both women and men optimize their health before pregnancy. With essential nutrients like Folate, Iodine, and Zinc, Beli ensures your body is ready for this exciting next step. Give yourself and your future baby the best foundation for a healthy start.Visit Belibaby.com today and use code IAF15 for 15% off your first order. Our Sponsors:* Sign up and get 10% off at BetterHelp dot com. Your emotional wellbeing matters. Find support and feel lighter in therapy. Support this podcast at — https://redcircle.com/infertile-af-infertility-and-modern-family-building-through-art/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
© 2020-2026 Ivy Podcast Discovery LLC
